Document:

Exhibit 10.8

 

EXECUTION VERSION

 

Subscription
Agreement

 

This SUBSCRIPTION AGREEMENT
(this “Subscription Agreement”) is entered into this 14th day of October, 2020, by and between Churchill Capital
Corp II, a Delaware corporation (the “Issuer”), and the undersigned (“Subscriber” or “you”).
Defined terms used but not otherwise defined herein shall have the respective meanings ascribed thereto in the Study Merger Agreement
(as defined below).

 

WHEREAS, Software Luxembourg
Holding S.A., a public limited liability company (société anonyme), incorporated and organized under the laws of
the Grand Duchy of Luxembourg, having its registered office at 48, Boulevard Grande-Duchesse Charlotte, L-1330 Luxembourg, Grand
Duchy of Luxembourg, and registered with the Luxembourg Register of Commerce and Companies (Registre de Commerce et des Sociétés,
Luxembourg) under number B246188 (“Study”), and the Issuer intend to effect a cross-border merger of Study with
and into the Issuer in accordance with the Agreement and Plan of Merger (the “Study Merger Agreement”), dated
as of October 12, 2020, by and among the Issuer and Study, the General Corporation Law of the State of Delaware, the provisions
of Directive 2017/1132 regarding certain aspects of company law issued by the European Parliament and Council on 14 June 2017,
which was transposed into Luxembourg law via Articles 1020-1 et seq. of the law of 10 August 1915 regarding commercial companies,
as amended, and a joint merger proposal, pursuant to which, among other things, Study will cease to exist and Study’s subsidiaries
shall become subsidiaries of the Issuer, which shall survive as the surviving corporation (the “Study Merger”
and, together with the other transactions contemplated by the Merger Agreement, the “Study Transactions”);

 

WHEREAS, following the
closing of the Study Transactions, the Issuer intends to effect a merger (the “Magnet Merger” and, together
with the other transactions contemplated by the Magnet Merger Agreement (as defined below), the “Magnet Transactions”
and, together with the Study Transactions, the “Transactions”) of Magnet Merger Sub, Inc., a Delaware corporation,
with and into Albert DE Holdings Inc., a Delaware corporation (“Magnet”), in accordance with the Agreement and
Plan of Merger (the “Magnet Merger Agreement”), dated as of October 12, 2020, by and among the Issuer, Merger
Sub and Magnet;

 

WHEREAS, in connection
with the Transactions, Subscriber desires to subscribe for and purchase from the Issuer 1,000,000 shares (the “Shares”)
of the Issuer’s Class A common stock, par value $0.0001 per share (the “Class A common stock”), for a
purchase price of $10.00 per share, for an aggregate purchase price of $10,000,000 (the “Purchase Price”), and
the Issuer desires to issue and sell to Subscriber the Shares in consideration of the payment of the Purchase Price therefor by
or on behalf of Subscriber to the Issuer, all on the terms and conditions set forth herein;

 

NOW, THEREFORE, in consideration
of the foregoing and the mutual representations, warranties and covenants, and subject to the conditions, herein contained, and
intending to be legally bound hereby, the parties hereto hereby agree as follows:

 

1.                  Subscription.
Subject to the terms and conditions hereof, at the Closing, Subscriber hereby agrees to subscribe for and purchase, and the
Issuer hereby agrees to issue and sell to Subscriber, upon the payment of the Purchase Price, the Shares (such subscription
and issuance, the “Subscription”).

 

     

     

    

 

2.                 
Representations, Warranties and Agreements.

 

2.1            
Subscriber’s Representations, Warranties and Agreements. To induce the Issuer to issue the Shares to Subscriber,
Subscriber hereby represents and warrants to the Issuer and acknowledges and agrees with the Issuer as follows:

 

2.1.1                     
Subscriber has been duly formed or incorporated and is validly existing in good standing under the laws of its jurisdiction
of incorporation or formation, with power and authority to enter into, deliver and perform its obligations under this Subscription
Agreement.

 

2.1.2                      
This Subscription Agreement has been duly authorized, validly executed and delivered by Subscriber. Assuming that this Subscription
Agreement constitutes the valid and binding agreement of the Issuer, this Subscription Agreement is the valid and binding obligation
of Subscriber, is enforceable against Subscriber in accordance with its terms, except as may be limited or otherwise affected by
(i) bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium or other laws relating to or affecting the rights
of creditors generally, and (ii) principles of equity, whether considered at law or equity.

 

2.1.3                     
The execution, delivery and performance by Subscriber of this Subscription Agreement and the consummation of the transactions
contemplated herein do not and will not (i) conflict with or result in a breach or violation of any of the terms or provisions
of, or constitute a default under, or result in the creation or imposition of any lien, charge or encumbrance upon any of the property
or assets of Subscriber or any of its subsidiaries pursuant to the terms of any indenture, mortgage, deed of trust, loan agreement,
lease, license or other agreement or instrument to which Subscriber or any of its subsidiaries is a party or by which Subscriber
or any of its subsidiaries is bound or to which any of the property or assets of Subscriber or any of its subsidiaries is subject,
which would reasonably be expected to have a material adverse effect on the ability of Subscriber to enter into and timely perform
its obligations under or consummate the transactions contemplated by this Subscription Agreement (a “Subscriber Material
Adverse Effect”), (ii) result in any violation of the provisions of the organizational documents of Subscriber or any
of its subsidiaries or (iii) result in any violation of any statute or any judgment, order, rule or regulation of any court or
governmental agency or body, domestic or foreign, having jurisdiction over Subscriber or any of its subsidiaries or any of their
respective properties that would reasonably be expected to have a Subscriber Material Adverse Effect.

 

2.1.4                      Subscriber
(i) is a “qualified institutional buyer” (as defined in Rule 144A under the Securities Act) or an
 “accredited investor” (within the meaning of Rule 501(a) under the Securities Act) satisfying the applicable
requirements set forth on Schedule I, (ii) is acquiring the Shares only for its own account and not for the account of
others, or if Subscriber is subscribing for the Shares as a fiduciary or agent for one or more investor accounts, each owner
of such account is a qualified institutional buyer, and Subscriber has full investment discretion with respect to each such
account, and the full power and authority to make the acknowledgements, representations, warranties and agreements herein on
behalf of each owner of each such account and (iii) is not acquiring the Shares with a view to, or for offer or sale in
connection with, any distribution thereof in violation of the Securities Act (and shall provide the requested information on Schedule
I following the signature page hereto). Subscriber is not an entity formed for the specific purpose of acquiring the
Shares.

 

    2

     

    

 

2.1.5                     
Subscriber understands that the Shares are being offered in a transaction not involving any public offering within the meaning
of the Securities Act and that the Shares have not been registered under the Securities Act. Subscriber understands that the Shares
may not be resold, transferred, pledged or otherwise disposed of by Subscriber absent an effective registration statement under
the Securities Act, except (i) to the Issuer or a subsidiary thereof, (ii) to non-U.S. persons pursuant to offers and sales that
occur solely outside the United States within the meaning of Regulation S under the Securities Act or (iii) pursuant to another
applicable exemption from the registration requirements of the Securities Act, and in each of cases (i) and (iii), in accordance
with any applicable securities laws of the states and other jurisdictions of the United States, and that any certificates representing
the Shares shall contain a legend to such effect. Subscriber acknowledges that the Shares will not be eligible for resale pursuant
to Rule 144A promulgated under the Securities Act. Subscriber understands and agrees that the Shares will be subject to transfer
restrictions and, as a result of these transfer restrictions, Subscriber may not be able to readily resell the Shares and may be
required to bear the financial risk of an investment in the Shares for an indefinite period of time. Subscriber understands that
it has been advised to consult legal counsel prior to making any offer, resale, pledge or transfer of any of the Shares.

 

2.1.6                     
Subscriber understands and agrees that Subscriber is purchasing the Shares directly from the Issuer. Subscriber further
acknowledges that there have been no representations, warranties, covenants or agreements made to Subscriber by the Issuer, Study
or any of their respective officers or directors, expressly or by implication, other than those representations, warranties, covenants
and agreements expressly set forth in this Subscription Agreement.

 

2.1.7                      
Subscriber represents and warrants that its acquisition and holding of the Shares will not constitute or result in a non-exempt
prohibited transaction under Section 406 of the Employee Retirement Income Security Act of 1974, as amended (“ERISA”),
Section 4975 of the Internal Revenue Code of 1986, as amended (the “Code”), or any applicable similar law.

 

2.1.8                      In
making its decision to purchase the Shares, Subscriber represents that it has relied solely upon independent investigation
made by Subscriber. Without limiting the generality of the foregoing, Subscriber has not relied on any statements or other
information provided by anyone other than the Issuer and its representatives concerning the Issuer or the Shares or the offer
and sale of the Shares. Subscriber acknowledges and agrees that Subscriber has received, has had an adequate opportunity to
review and has reviewed such financial and other information as Subscriber deems necessary in order to make an investment
decision with respect to the Shares, including with respect to the Issuer, Study, Magnet and the Transactions and has made
its own assessment and is satisfied concerning the relevant tax and other economic considerations relevant to
Subscriber’s investment in the Shares. Subscriber represents and agrees that Subscriber and Subscriber’s
professional advisor(s), if any, have had the full opportunity to ask such questions, receive such answers and obtain such
information as Subscriber and such Subscriber’s professional advisor(s), if any, have deemed necessary to make an
investment decision with respect to the Shares.

 

    3

     

    

 

2.1.9                     
Subscriber became aware of this offering of the Shares solely by means of direct contact between Subscriber and the Issuer
or its representative. Subscriber has a pre-existing substantive relationship (as interpreted in guidance from the Commission under
the Securities Act) with the Issuer or its representative, and the Shares were offered to Subscriber solely by direct contact between
Subscriber and the Issuer or its representative. Subscriber did not become aware of this offering of the Shares, nor were the Shares
offered to Subscriber, by any other means. Subscriber acknowledges that the Shares (i) were not offered by any form of general
solicitation or general advertising, including methods described in section 502(c) of Regulation D under the Securities Act and
(ii) are not being offered in a manner involving a public offering under, or in a distribution in violation of, the Securities
Act, or any state securities laws.

 

2.1.10                   
Subscriber acknowledges that it is aware that there are substantial risks incident to the purchase and ownership of the
Shares. Subscriber has such knowledge and experience in financial and business matters as to be capable of evaluating the merits
and risks of an investment in the Shares, and Subscriber has sought such accounting, legal and tax advice as Subscriber has considered
necessary to make an informed investment decision.

 

2.1.11                  
Alone, or together with any professional advisor(s), Subscriber represents and acknowledges that Subscriber has adequately
analyzed and fully considered the risks of an investment in the Shares and determined that the Shares are a suitable investment
for Subscriber and that Subscriber is able at this time and in the foreseeable future to bear the economic risk of a total loss
of Subscriber’s investment in the Issuer. Subscriber acknowledges specifically that a possibility of total loss exists.

 

2.1.12                   
Subscriber understands and agrees that no federal or state agency has passed upon or endorsed the merits of the offering
of the Shares or made any findings or determination as to the fairness of an investment in the Shares.

 

2.1.13                    Subscriber
represents and warrants that Subscriber is not (i) a person or entity named on the List of Specially Designated Nationals and
Blocked Persons administered by the U.S. Treasury Department’s Office of Foreign Assets Control
(“OFAC”) or in any Executive Order issued by the President of the United States and administered by OFAC
(“OFAC List”), or a person or entity prohibited by any OFAC sanctions program, (ii) a Designated National
as defined in the Cuban Assets Control Regulations, 31 C.F.R. Part 515 or (iii) a non-U.S. shell bank or providing banking
services indirectly to a non-U.S. shell bank. Subscriber agrees to provide law enforcement agencies, if requested thereby,
such records as required by applicable law, provided that Subscriber is permitted to do so under applicable law. Subscriber
represents that if it is a financial institution subject to the Bank Secrecy Act (31 U.S.C. Section 5311 et seq.) (the
 “BSA”), as amended by the USA PATRIOT Act of 2001 (the “PATRIOT Act”), and its
implementing regulations (collectively, the “BSA/PATRIOT Act”), that Subscriber maintains policies and
procedures reasonably designed to comply with applicable obligations under the BSA/PATRIOT Act. Subscriber also represents
that, to the extent required, it maintains policies and procedures reasonably designed for the screening of its investors
against the OFAC sanctions programs, including the OFAC List. Subscriber further represents and warrants that, to the extent
required, it maintains policies and procedures reasonably designed to ensure that the funds held by Subscriber and used to
purchase the Shares were legally derived.

 

    4

     

    

 

2.1.14                   
Subscriber is not an employee benefit plan that is subject to Title I of ERISA, a plan, an individual retirement account
or other arrangement that is subject to section 4975 of the Code or an employee benefit plan that is a governmental plan (as defined
in section 3(32) of ERISA), a church plan (as defined in section 3(33) of ERISA), a non-U.S. plan (as described in section 4(b)(4)
of ERISA) or other plan that is not subject to the foregoing but may be subject to provisions under any other federal, state, local,
non-U.S. or other laws or regulations that are similar to such provisions of ERISA or the Code, or an entity whose underlying assets
are considered to include “plan assets” of any such plan, account or arrangement subject to the fiduciary or prohibited
transaction provisions of ERISA or section 4975 of the Code.

 

2.1.15                   
Except as expressly disclosed in a Schedule 13D or Schedule 13G (or amendments thereto) filed by such Subscriber with the
Commission with respect to the beneficial ownership of the Issuer’s common stock, Subscriber is not currently (and at all
times through Closing will refrain from being or becoming) a member of a “group” (within the meaning of Section 13(d)(3)
or Section 14(d)(2) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or any successor
provision), including any group acting for the purpose of acquiring, holding or disposing of equity securities of the Issuer (within
the meaning of Rule 13d-5(b)(1) under the Exchange Act).

 

2.1.16                   
Subscriber will not acquire a substantial interest (as defined in 31 C.F.R. Part 800.244) in the Issuer as a result of the
purchase and sale of Shares hereunder such that a declaration to the Committee on Foreign Investment in the United States would
be mandatory under 31 C.F.R. Part 800.401, and Subscriber will not have control (as defined in 31 C.F.R. Part 800.208) over the
Issuer from and after the Closing as a result of the purchase and sale of Shares hereunder.

 

2.1.17                    Subscriber
has, and on each date the Purchase Price would be required to be funded to the Issuer pursuant to Section 3.1 will
have, sufficient immediately available funds to pay the Purchase Price pursuant to Section 3.1. Subscriber is an
entity having total liquid assets and net assets in excess of the Purchase Price as of the date hereof and as of each date
the Purchase Price would be required to be funded to the Issuer pursuant to Section 3.1 and was not formed for the
purpose of acquiring the Shares.

 

    5

     

    

 

2.1.18                   
None of the information provided or to be provided in writing by or on behalf of Subscriber for inclusion in the Joint Proxy
Statement or Joint Proxy Statement/Prospectus (each, as defined in the Study Merger Agreement) will contain any untrue statement
or a material fact or omit to state any material fact necessary in order to make the statements therein, in light of the circumstances
under which they were made, not misleading.

 

2.1.19                   
No broker, finder or other financial consultant has acted on behalf of Subscriber in connection with this Subscription Agreement
or the transactions contemplated hereby in such a way as to create any liability on the Issuer.

 

2.2             
Issuer’s Representations, Warranties and Agreements. To induce Subscriber to purchase the Shares, the Issuer
hereby represents and warrants to Subscriber and agrees with Subscriber as follows:

 

2.2.1                      
The Issuer has been duly incorporated and is validly existing as a corporation in good standing under the laws of the Delaware
General Corporation Law (“DGCL”), with corporate power and authority to own, lease and operate its properties
and conduct its business as presently conducted and to enter into, deliver and perform its obligations under this Subscription
Agreement.

 

2.2.2                      
When issued and delivered to Subscriber against full payment for the Shares in accordance with the terms of this Subscription
Agreement and registered with the Issuer’s transfer agent, the Shares will be duly authorized, validly issued, fully paid
and non-assessable and will not have been issued in violation of or subject to any preemptive or similar rights created under the
Issuer’s amended and restated certificate of incorporation (the “Charter”) or under the DGCL.

 

2.2.3                      
This Subscription Agreement has been duly authorized, validly executed and delivered by the Issuer and, assuming that this
Subscription Agreement constitutes the valid and binding obligation of Subscriber, is the valid and binding obligation of the Issuer,
is enforceable against the Issuer in accordance with its terms, except as may be limited or otherwise affected by (i) bankruptcy,
insolvency, fraudulent conveyance, reorganization, moratorium or other laws relating to or affecting the rights of creditors generally
and (ii) principles of equity, whether considered at law or equity.

 

2.2.4                      
The Issuer is classified as a Subchapter C corporation for U.S. federal income tax purposes.

 

    6

     

    

 

2.2.5                       The
execution, delivery and performance of this Subscription Agreement (including compliance by the Issuer with all of the
provisions hereof), issuance and sale of the Shares and the consummation of the certain other transactions contemplated
herein will not, subject to the receipt of the Buyer Stockholder Approval and the effectiveness of the Buyer A&R Charter
Amendment, (i) conflict with or result in a breach or violation of any of the terms or provisions of, or constitute a default
under, or result in the creation or imposition of any lien, charge or encumbrance upon any of the property or assets of the
Issuer pursuant to the terms of any indenture, mortgage, deed of trust, loan agreement, lease, license or other agreement or
instrument to which the Issuer is a party or by which the Issuer is bound or to which any of the property or assets of the
Issuer is subject, which would reasonably be expected to have a material adverse effect on the legal authority of the Issuer
to enter into and timely perform its obligations under this Subscription Agreement (a “Issuer Material Adverse
Effect”), (ii) result in any violation of the provisions of the organizational documents of the Issuer or (iii)
result in any violation of any statute or any judgment, order, rule or regulation of any court or governmental agency or
body, domestic or foreign, having jurisdiction over the Issuer or any of its properties that would reasonably be expected to
have an Issuer Material Adverse Effect.

 

2.2.6                      
Neither the Issuer, nor any person acting on its behalf has, directly or indirectly, made any offers or sales of any Issuer
security or solicited any offers to buy any security under circumstances that would adversely affect reliance by the Issuer on
Section 4(a)(2) of the Securities Act for the exemption from registration for the transactions contemplated hereby or would require
registration of the issuance of the Shares under the Securities Act.

 

2.2.7                      
Neither the Issuer nor any person acting on its behalf has conducted any general solicitation or general advertising, including
methods described in section 502(c) of Regulation D under the Securities Act, in connection with the offer or sale of any of the
Shares and neither the Issuer nor any person acting on its behalf offered any of the Shares in a manner involving a public offering
under, or in a distribution in violation of, the Securities Act or any state securities laws.

 

2.2.8                      
[reserved]

 

2.2.9                       As
of the date of this Subscription Agreement, the authorized capital shares of the Issuer consists of (a) 200,000,000 shares of
Class A common stock, (b) 20,000,000 shares of Class B common stock, par value $0.0001 per share (“Class B common
stock”); and (c) 1,000,000 shares of preferred stock, par value $0.0001 per share (“Preferred
Shares”). As of the date hereof: (i) no Preferred Shares are issued and outstanding; (ii) 69,000,000 shares of
Class A common stock are issued and outstanding; (iii) 17,250,000 shares of Class B common stock are issued and outstanding;
(iv) 15,800,000 warrants to purchase 15,800,000 shares of Class A common stock (the “Private Placement
Warrants”) are outstanding; and (v) 23,000,000 warrants to purchase 23,000,000 shares of Class A common stock (the
 “Public Warrants”) are outstanding. Subject to the receipt of the Buyer Stockholder Approval and the
effectiveness of the Buyer A&R Charter Amendment, all (i) issued and outstanding shares of Class A common stock and Class
B common stock have been duly authorized and validly issued, are fully paid and are non-assessable and are not subject to
preemptive rights and (ii) outstanding Private Placement Warrants and Public Warrants have been duly authorized and validly
issued, are fully paid and are not subject to preemptive rights. Except as set forth above and as contemplated by the Study
Merger Agreement or the Magnet Merger Agreement and except in respect of any Class A common stock or any warrants exercisable
for shares of Class A common stock after the date hereof at a purchase price, or at an exercise price, as applicable, equal
to or greater than ten dollars ($10.00) per share (before calculating any transaction expenses, original issue discounts or
other similar premiums, charges and expenses that are customary for issuances of equity or equity-linked securities in
connection with a private investment in a public company), there are no outstanding options, warrants or other rights to
subscribe for, purchase or acquire from the Issuer any shares of Class A common stock or Class B common stock, or any other
equity interests in the Issuer, or securities convertible into or exchangeable or exercisable for such equity interests. As
of the date hereof, the Issuer has no subsidiaries and does not own, directly or indirectly, interests or investments
(whether equity or debt) in any person, whether incorporated or unincorporated. There are no stockholder agreements, voting
trusts or other agreements or understandings to which the Issuer is a party or by which it is bound relating to the voting of
any securities of the Issuer, other than (A) as set forth in the SEC Documents and (B) as contemplated by the Study Merger
Agreement.

 

    7

     

    

 

2.2.10                   
Assuming the accuracy of Subscriber’s representations and warranties set forth in Section 2.1 of this Subscription
Agreement, (x) no registration under the Securities Act is required for the offer and sale of the Shares by the Issuer to Subscriber
and (y) no consent, approval, order or authorization of, or registration, qualification, designation, declaration or filing with,
any federal, state or local governmental authority is required on the part of the Issuer in connection with the consummation of
the transactions contemplated by this Subscription Agreement, except for (i) filings pursuant to Regulation D of the Securities
Act and applicable state securities laws, (ii) filings required by the NYSE, including with respect to obtaining shareholder approval,
(iii) filings required to consummate the Transactions as provided under the definitive documents relating to the Transactions and
(iv) where the failure of which to obtain would not be reasonably likely to have an Issuer Material Adverse Effect.

 

2.2.11                    The
Issuer has made available to Subscriber (including via the Securities and Exchange Commission’s (the
 “Commission”) EDGAR system) a true, correct and complete copy of each form, report, statement, schedule,
prospectus, proxy, registration statement and other documents filed by the Issuer with the Commission prior to the date of
this Subscription Agreement (the “SEC Documents”). None of the SEC Documents filed under the Exchange Act,
contained, when filed or, if amended prior to the date of this Subscription Agreement, as of the date of such amendment with
respect to those disclosures that are amended, any untrue statement of a material fact or omitted to state a material fact
required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they
were made, not misleading. The Issuer has timely filed each report, statement, schedule, prospectus, and registration
statement that the Issuer was required to file with the Commission since its inception and through the date hereof. As of the
date hereof, there are no material outstanding or unresolved comments in comment letters from the Commission staff with
respect to any of the SEC Documents.

 

    8

     

    

 

2.2.12                  
As of the date hereof, there are no pending or, to the knowledge of the Issuer, threatened, claims, actions, suits, arbitrations,
litigation or proceedings (“Actions”), which, if determined adversely, would, individually or in the aggregate,
reasonably be expected to have a material adverse effect on the ability of the Issuer to enter into and perform its obligations
under this Subscription Agreement. As of the date hereof, there is no unsatisfied judgment or any open injunction binding upon
the Issuer which would, individually or in the aggregate, reasonably be expected to have a material adverse effect on the ability
of the Issuer to enter into and perform its obligations under this Subscription Agreement.

 

2.2.13                  
No broker, finder or other financial consultant has acted on behalf of Issuer in connection with this Subscription Agreement
or the transactions contemplated hereby in such a way as to create any liability on Subscriber. The Issuer agrees to indemnify
and hold harmless Subscriber from any claim or demand for commission or other compensation by any broker, finder, financial consultant
or similar agent claiming to have been employed by or on behalf of Issuer and to bear the cost of legal expenses incurred by Subscriber
in defending against any such claim.

 

2.2.14                  
The execution, delivery and performance of its obligations hereunder by Subscriber are, or are based on, commercial acts
for purposes of applicable law.

 

2.2.15                  
The Class A common stock of the Issuer is registered pursuant to Section 12(b) of the Exchange Act, and listed for trading
on the New York Stock Exchange (“NYSE”). There is no suit, action, proceeding or investigation pending or, to
the knowledge of the Issuer, threatened against the Issuer by the NYSE or the Commission with respect to any intention by such
entity to deregister the Class A common stock or prohibit or terminate the listing of the Class A common stock on the NYSE. The
Issuer has taken no action that is designed to terminate the registration of the Class A common stock under the Exchange Act.

 

3.                 
Settlement Date and Delivery.

 

3.1              Closing.
The closing of the Subscription contemplated hereby (the “Closing”) shall occur on the date of, and
immediately prior to, the consummation of the Study Transactions. Upon written notice from (or on behalf of) the Issuer to
Subscriber (the “Closing Notice”) at least ten (10) Business Days prior to the date that the Issuer
reasonably expects all conditions to the closing of the Study Transactions to be satisfied (the “Expected Closing
Date”), Subscriber shall deliver to the Issuer no later than two (2) Business Days prior to the Expected Closing
Date, the Purchase Price for the Shares, by wire transfer of United States dollars in immediately available funds to the
account specified by the Issuer in the Closing Notice, such funds to be held by the Issuer in escrow until the Closing. If
the Study Transactions are not consummated on or prior to the tenth (10th) Business Day after the Expected Closing Date, the
Issuer shall return the Purchase Price to Subscriber by wire transfer of United States dollars in immediately available funds
to an account specified by Subscriber. Notwithstanding such return, (i) a failure to close on the Expected Closing Date
shall not, by itself, be deemed to be a failure of any of the conditions to Closing set forth in this Section 3
to be satisfied or waived on or prior to the Closing Date, and (ii) Subscriber shall remain obligated (A) to redeliver
funds to the Issuer following the Issuer’s delivery to Subscriber of a new Closing Notice and (B) to consummate the
Closing upon satisfaction of the conditions set forth in this Section 3. Unless otherwise agreed by Study in
writing, the Issuer shall deliver the Closing Notice at least eight (8) Business Days prior to the date of the Special
Meeting. At the Closing, upon satisfaction (or, if applicable, waiver) of the conditions set forth in this Section 3,
the Issuer shall deliver to Subscriber the Shares in certificated or book entry form (at the Issuer’s election), in the
name of Subscriber (or its nominee in accordance with its delivery instructions) or to a custodian designated by Subscriber,
as applicable. For purposes of this Subscription Agreement, “Business Day” means any day that, in New
York, New York, is neither a legal holiday nor a day on which banking institutions are generally authorized or required by
law or regulation to close.

 

    9

     

    

 

3.2             
Conditions to Closing of the Issuer.

 

The Issuer’s obligations
to sell and issue the Shares at the Closing are subject to the fulfillment or (to the extent permitted by applicable law) written
waiver by Issuer, on or prior to the Closing Date, of each of the following conditions:

 

3.2.1                      
Representations and Warranties Correct. The representations and warranties made by Subscriber in Section 2.1
hereof shall be true and correct in all material respects when made (other than representations and warranties that are qualified
as to materiality or Subscriber Material Adverse Effect, which representations and warranties shall be true and correct in all
respects), and shall be true and correct in all material respects on and as of the Closing Date (unless they specifically speak
as of another date in which case they shall be true and correct in all material respects as of such date) (other than representations
and warranties that are qualified as to materiality or Subscriber Material Adverse Effect, which representations and warranties
shall be true in all respects) with the same force and effect as if they had been made on and as of said date, but in each case
without giving effect to consummation of the Transactions.

 

3.2.2                      
Compliance with Covenants. Subscriber shall have performed, satisfied and complied in all material respects with
the covenants, agreements and conditions required by this Subscription Agreement to be performed, satisfied or complied with by
Subscriber at or prior to the Closing.

 

3.2.3                     
Closing of the Study Transactions. All conditions precedent to the Issuer’s obligations to consummate, or cause
to be consummated, the Study Transactions set forth in the Study Merger Agreement shall have been satisfied or waived by the party
entitled to the benefit thereof under the Study Merger Agreement (other than those conditions that may only be satisfied at the
consummation of the Study Transactions, but subject to satisfaction or waiver by such party of such conditions as of the consummation
of the Study Transactions), and the Study Transactions will be consummated immediately following the Closing.

 

    10

     

    

 

3.2.4                   
 Legality. There shall not be in force any order, judgment, injunction, decree, writ, stipulation, determination
or award, in each case, entered by or with any governmental authority, statute, rule or regulation enjoining or prohibiting the
consummation of the Subscription.

 

3.3             
Conditions to Closing of Subscriber.

 

Subscriber’s obligation
to purchase the Shares at the Closing is subject to the fulfillment or (to the extent permitted by applicable law) written waiver
by Subscriber, on or prior to the Closing Date, of each of the following conditions:

 

3.3.1                      
Representations and Warranties Correct. The representations and warranties made by the Issuer in Section 2.2
hereof shall be true and correct in all material respects when made (other than representations and warranties that are qualified
as to materiality or Issuer Material Adverse Effect, which representations and warranties shall be true and correct in all respects),
and shall be true and correct in all material respects on and as of the Closing Date (unless they specifically speak as of another
date in which case they shall be true and correct in all material respects as of such date) (other than representations and warranties
that are qualified as to materiality or Issuer Material Adverse Effect, which representations and warranties shall be true and
correct in all respects) with the same force and effect as if they had been made on and as of said date, but in each case without
giving effect to consummation of the Transactions; provided, that in the event this condition would otherwise fail to be
satisfied as a result of a breach of one or more of the representations and warranties of the Issuer contained in this Subscription
Agreement and the facts underlying such breach would also cause a condition to Study’s obligations under the Study Merger
Agreement to fail to be satisfied, this condition shall nevertheless be deemed satisfied in the event Study waives such condition
with respect to such breach under the Study Merger Agreement.

 

3.3.2                      
Compliance with Covenants. The Issuer shall have performed, satisfied and complied in all material respects with
the covenants, agreements and conditions required by this Subscription Agreement to be performed, satisfied or complied with by
the Issuer at or prior to the Closing, except where the failure of such performance or compliance would not or would not reasonably
be expected to prevent, materially delay, or materially impair the ability of the Issuer to consummate the Closing.

 

3.3.3                       Closing
of the Study Transactions. (i) All conditions precedent to the consummation of the Study Transactions set forth in the
Study Merger Agreement shall have been satisfied or waived by the party entitled to the benefit thereof under the Study
Merger Agreement (other than those conditions that may only be satisfied at the consummation of the Study Transactions, but
subject to satisfaction or waiver by such party of such conditions as of the consummation of the Study Transactions), (ii) no
amendment or modification of the Study Merger Agreement (as the same exists on the date hereof as provided to Subscriber)
shall have occurred that would reasonably be expected to materially and adversely affect the economic benefits that
Subscriber would reasonably expect to receive under this Subscription Agreement without having received Subscriber’s
prior written consent (not to be unreasonably withheld, conditioned or delayed) and (iii) the Study Transactions will be
consummated immediately following the Closing.

 

    11

     

    

 

 

3.3.4                      
Legality. There shall not be in force any order, judgment, injunction, decree, writ, stipulation, determination or
award, in each case, entered by or with any governmental authority, statute, rule or regulation enjoining or prohibiting the transactions
contemplated by this Subscription Agreement.

 

3.3.5                      
Issuer Stockholder Approval. To the extent required by the listing rules of NYSE, approval of the issuance of the
Shares pursuant to this Subscription Agreement by the Issuer’s stockholders shall have been obtained.

 

4.                 
Registration Statement. Prior to or concurrently with the Closing, the parties shall enter into a joinder,
or otherwise become a party, to the Amended and Registration Rights Agreement, dated as of October 12, 2020, by and among the Issuer,
Study, Churchill Sponsor II, LLC and the other parties thereto.

 

5.                 
Termination. This Subscription Agreement shall terminate and be void and of no further force and effect, and
all rights and obligations of the parties hereunder shall terminate without any further liability on the part of any party in respect
thereof, upon the earlier to occur of (i) such date and time as the Study Merger Agreement is validly terminated in accordance
with its terms and (ii) upon the mutual written agreement of each of the parties hereto to terminate this Subscription Agreement;
provided, that nothing herein will relieve any party from liability for any willful breach hereof prior to the time of termination,
and each party will be entitled to any remedies at law or in equity to recover losses, liabilities or damages arising from such
breach. The Issuer shall promptly notify Subscriber of (i) the termination of the Study Merger Agreement promptly after the termination
of such agreement, and (ii) any waiver by the Issuer of any of the conditions specified in Article X of the Study Merger Agreement.

 

6.                 
Miscellaneous.

 

6.1             
Further Assurances. At the Closing, the parties hereto shall execute and deliver such additional documents and take
such additional actions as the parties reasonably may deem to be practical and necessary in order to consummate the Subscription
as contemplated by this Subscription Agreement.

 

6.1.1                    
Subscriber acknowledges that the Issuer, Study and others will rely on the acknowledgments, understandings, agreements,
representations and warranties made by Subscriber contained in this Subscription Agreement. Prior to the Closing, Subscriber agrees
to promptly notify the Issuer and Study if any of the acknowledgments, understandings, agreements, representations and warranties
set forth herein are no longer accurate in all material respects.

 

6.1.2                       Each
of the Issuer, Subscriber and Study is entitled to rely upon this Subscription Agreement and is irrevocably authorized to
produce this Subscription Agreement or a copy hereof to any interested party in any administrative or legal proceeding or
official inquiry with respect to the matters covered hereby.

 

    12

     

    

 

6.1.3                      
The Issuer may request from Subscriber such additional information as the Issuer may deem necessary to evaluate the eligibility
of Subscriber to acquire the Shares, and Subscriber shall provide such information as may be reasonably requested, to the extent
within Subscriber’s possession and control or otherwise readily available to Subscriber.

 

6.1.4                      
Each of Subscriber and the Issuer shall pay all of its own expenses in connection with this Subscription Agreement and the
transactions contemplated herein.

 

6.1.5                      
Each of Subscriber and the Issuer shall take, or cause to be taken, all actions and do, or cause to be done, all things
necessary, proper or advisable to consummate the transactions contemplated by this Subscription Agreement on the terms and conditions
described therein no later than immediately prior to the consummation of the Study Transactions.

 

6.2             
Notices. Any notice or communication required or permitted hereunder shall be in writing and either delivered personally,
emailed or sent by overnight mail via a reputable overnight carrier, or sent by certified or registered mail, postage prepaid,
and shall be deemed to be given and received (i) when so delivered personally, (ii) when sent, with no mail undeliverable or other
rejection notice, if sent by email, or (iii) three (3) Business Days after the date of mailing to the address below or to such
other address or addresses as such person may hereafter designate by notice given hereunder:

 

(i)       if
to Subscriber, to:

 

(ii)      if to
the Issuer, to:

 

Churchill Capital
Corp. II

640 Fifth Avenue,
12th Floor

New York, NY
10019

Attention:      Michael
S. Klein

Telephone:    212-380-7775

Email:           Michael.klein@mkleinandcompany.com

 

with a required
copy (which copy shall not constitute notice) to:

 

Paul, Weiss,
Rifkind, Wharton & Garrison LLP

1285 Avenue of
the Americas

New York, NY
10019

Attention: Ross
A. Fieldston, Raphael M. Russo

Email: rfieldston@paulweiss.com;
rrusso@paulweiss.com

 

    13

     

    

 

6.3             
Entire Agreement. This Subscription Agreement constitutes the entire agreement, and supersedes all other prior agreements,
understandings, representations and warranties, both written and oral, among the parties, with respect to the subject matter hereof,
including any commitment letter entered into relating to the subject matter hereof.

 

6.4             
Modifications and Amendments. This Subscription Agreement may not be amended, modified, supplemented or waived (i)
except by an instrument in writing, signed by the party against whom enforcement of such amendment, modification, supplement or
waiver is sought and (ii) without the prior written consent of Study (with respect to this clause (ii), solely to the extent that
an amendment, modification, supplement or waiver would reasonably be expected to materially and adversely affect the Issuer’s
ability to consummate the Study Transactions); provided that any rights (but not obligations) of a party under this Subscription
Agreement may be waived, in whole or in part, by such party on its own behalf without the prior consent of any other party.

 

6.5             
Assignment. Neither this Subscription Agreement nor any rights, interests or obligations that may accrue to the parties
hereunder (including Subscriber’s rights to purchase the Shares) may be transferred or assigned without the prior written
consent of each of the other parties hereto (other than the Shares acquired hereunder, if any, and then only in accordance with
this Subscription Agreement); provided that Subscriber’s rights and obligations hereunder may be assigned to any fund or
account managed by the same investment manager as Subscriber, without the prior consent of the Issuer, provided that such assignee(s)
agrees in writing to be bound by the terms hereof, and upon such assignment by a Subscriber, the assignee(s) shall become Subscriber
hereunder and have the rights and obligations and be deemed to make the representations and warranties of Subscriber provided for
herein to the extent of such assignment; provided, further, that no assignment shall relieve the assigning party
of any of its obligations hereunder, including any assignment to any fund or account managed by the same investment manager as
Subscriber.

 

6.6             
Benefit.

 

6.6.1                      
Except as otherwise provided herein, this Subscription Agreement shall be binding upon, and inure to the benefit of the
parties hereto and their heirs, executors, administrators, successors, legal representatives, and permitted assigns, and the agreements,
representations, warranties, covenants and acknowledgments contained herein shall be deemed to be made by, and be binding upon,
such heirs, executors, administrators, successors, legal representatives and permitted assigns. This Subscription Agreement shall
not confer rights or remedies upon any person other than the parties hereto and their respective successors and assigns.

 

6.7              Governing
Law. This Subscription Agreement, and any claim or cause of action hereunder based upon, arising out of or related to
this Subscription Agreement (whether based on law, in equity, in contract, in tort or any other theory) or the negotiation,
execution, performance or enforcement of this Subscription Agreement, shall be governed by and construed in accordance with
the laws of the State of Delaware, without giving effect to the principles of conflicts of law thereof.

 

    14

     

    

 

6.8             
Consent to Jurisdiction; Waiver of Jury Trial. Each of the parties irrevocably consents to the exclusive jurisdiction
and venue of the Court of Chancery of the State of Delaware, provided, that if subject matter jurisdiction over the matter
that is the subject of the legal proceeding is vested exclusively in the U.S. federal courts, such legal proceeding shall be heard
in the U.S. District Court for the District of Delaware (together with the Court of Chancery of the State of Delaware “Chosen
Courts”), in connection with any matter based upon or arising out of this Subscription Agreement. Each party hereby waives,
and shall not assert as a defense in any legal dispute, that (i) such person is not personally subject to the jurisdiction of the
Chosen Courts for any reason, (ii) such legal proceeding may not be brought or is not maintainable in the Chosen Courts, (iii)
such person’s property is exempt or immune from execution, (iv) such legal proceeding is brought in an inconvenient forum
or (v) the venue of such legal proceeding is improper. Each party hereby consents to service of process in any such proceeding
in any manner permitted by Delaware law, further consents to service of process by nationally recognized overnight courier service
guaranteeing overnight delivery, or by registered or certified mail, return receipt requested, at its address specified pursuant
to Section 6.2 and waives and covenants not to assert or plead any objection which they might otherwise have to such manner
of service of process. Notwithstanding the foregoing in this Section 6.8, a party may commence any action, claim, cause
of action or suit in a court other than the Chosen Courts solely for the purpose of enforcing an order or judgment issued by the
Chosen Courts. TO THE EXTENT NOT PROHIBITED BY APPLICABLE LAW WHICH CANNOT BE WAIVED, EACH OF THE PARTIES WAIVES ANY RIGHT TO TRIAL
BY JURY ON ANY CLAIMS OR COUNTERCLAIMS ASSERTED IN ANY LEGAL DISPUTE RELATING TO THIS SUBSCRIPTION AGREEMENT WHETHER NOW EXISTING
OR HEREAFTER ARISING. IF THE SUBJECT MATTER OF ANY SUCH LEGAL DISPUTE IS ONE IN WHICH THE WAIVER OF JURY TRIAL IS PROHIBITED, NO
PARTY SHALL ASSERT IN SUCH LEGAL DISPUTE A NONCOMPULSORY COUNTERCLAIM ARISING OUT OF OR RELATING TO THIS SUBSCRIPTION AGREEMENT.
FURTHERMORE, NO PARTY SHALL SEEK TO CONSOLIDATE ANY SUCH LEGAL DISPUTE WITH A SEPARATE ACTION OR OTHER LEGAL PROCEEDING IN WHICH
A JURY TRIAL CANNOT BE WAIVED.

 

6.9             
Severability. If any provision of this Subscription Agreement shall be invalid, illegal or unenforceable, the validity,
legality or enforceability of the remaining provisions of this Subscription Agreement shall not in any way be affected or impaired
thereby and shall continue in full force and effect.

 

6.10          No
Waiver of Rights, Powers and Remedies. No failure or delay by a party hereto in exercising any right, power or remedy
under this Subscription Agreement, and no course of dealing between the parties hereto, shall operate as a waiver of any such
right, power or remedy of such party. No single or partial exercise of any right, power or remedy under this Subscription
Agreement by a party hereto, nor any abandonment or discontinuance of steps to enforce any such right, power or remedy, shall
preclude such party from any other or further exercise thereof or the exercise of any other right, power or remedy hereunder.
The election of any remedy by a party hereto shall not constitute a waiver of the right of such party to pursue other
available remedies. No notice to or demand on a party not expressly required under this Subscription Agreement shall entitle
the party receiving such notice or demand to any other or further notice or demand in similar or other circumstances or
constitute a waiver of the rights of the party giving such notice or demand to any other or further action in any
circumstances without such notice or demand.

 

    15

     

    

 

6.11            
Remedies.

 

6.11.1                  
The parties agree that the irreparable damage would occur if this Subscription Agreement was not performed or the Closing
is not consummated in accordance with its specific terms or was otherwise breached and that money damages or other legal remedies
would not be an adequate remedy for any such damage. It is accordingly agreed that the parties hereto shall be entitled to equitable
relief, including in the form of an injunction or injunctions, to prevent breaches or threatened breaches of this Subscription
Agreement and to enforce specifically the terms and provisions of this Subscription Agreement in an appropriate court of competent
jurisdiction as set forth in Section 6.8, this being in addition to any other remedy to which any party is entitled at law
or in equity, including money damages.  The right to specific enforcement shall include the right of the parties hereto to
cause to cause the other parties hereto to cause the transactions contemplated hereby to be consummated on the terms and subject
to the conditions and limitations set forth in this Subscription Agreement. The parties hereto further agree (i) to waive any requirement
for the security or posting of any bond in connection with any such equitable remedy, (ii) not to assert that a remedy of specific
enforcement pursuant to this Section 6.11 is unenforceable, invalid, contrary to applicable law or inequitable for any reason
and (iii) to waive any defenses in any action for specific performance, including the defense that a remedy at law would be adequate.

 

6.11.2                  
 The parties acknowledge and agree that this Section 6.11 is an integral part of the transactions contemplated hereby
and without that right, the parties hereto would not have entered into this Subscription Agreement.

 

6.11.3   
In any dispute arising out of or related to this Subscription Agreement, or any other agreement, document, instrument or
certificate contemplated hereby, or any transactions contemplated hereby or thereby, the applicable adjudicating body shall award
to the prevailing party, if any, the costs and attorneys’ fees reasonably incurred by the prevailing party in connection
with the dispute and the enforcement of its rights under this Subscription Agreement or any other agreement, document, instrument
or certificate contemplated hereby and, if the adjudicating body determines a party to be the prevailing party under circumstances
where the prevailing party won on some but not all of the claims and counterclaims, the adjudicating body may award the prevailing
party an appropriate percentage of the costs and attorneys’ fees reasonably incurred by the prevailing party in connection
with the adjudication and the enforcement of its rights under this Subscription Agreement or any other agreement, document, instrument
or certificate contemplated hereby or thereby.

 

6.12          Survival
of Representations and Warranties. All representations and warranties made by the parties hereto in this Subscription
Agreement shall survive the Closing. For the avoidance of doubt, if for any reason the Closing does not occur prior to the
consummation of the Study Transactions, all representations, warranties, covenants and agreements of the parties hereunder
shall survive the consummation of the Study Transactions and remain in full force and effect.

 

    16

     

    

 

6.13         
No Broker or Finder. Each of the Issuer and Subscriber agrees to indemnify and hold the other parties hereto harmless
from any claim or demand for commission or other compensation by any broker, finder, financial consultant or similar agent claiming
to have been employed by or on behalf of such party and to bear the cost of legal expenses incurred in defending against any such
claim.

 

6.14         
Headings and Captions. The headings and captions of the various subdivisions of this Subscription Agreement are for
convenience of reference only and shall in no way modify or affect the meaning or construction of any of the terms or provisions
hereof.

 

6.15         
Counterparts. This Subscription Agreement may be executed in one or more counterparts, all of which when taken together
shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and
delivered to the other parties, it being understood that the parties need not sign the same counterpart. In the event that any
signature is delivered by facsimile transmission or any other form of electronic delivery, such signature shall create a valid
and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as
if such signature page were an original thereof.

 

6.16         
Construction. The words “include,” “includes,” and “including”
will be deemed to be followed by “without limitation.” Pronouns in masculine, feminine, and neuter genders will
be construed to include any other gender, and words in the singular form will be construed to include the plural and vice versa,
unless the context otherwise requires. The words “this Subscription Agreement,” “herein,”
 “hereof,” “hereby,” “hereunder,” and words of similar import refer to
this Subscription Agreement as a whole and not to any particular subdivision unless expressly so limited. The parties hereto intend
that each representation, warranty, and covenant contained herein will have independent significance. If any party hereto has breached
any representation, warranty, or covenant contained herein in any respect, the fact that there exists another representation, warranty
or covenant relating to the same subject matter (regardless of the relative levels of specificity) which such party hereto has
not breached will not detract from or mitigate the fact that such party hereto is in breach of the first representation, warranty,
or covenant. All references in this Subscription Agreement to numbers of shares, per share amounts and purchase prices shall be
appropriately adjusted to reflect any stock split, stock dividend, stock combination, recapitalization or the like occurring after
the date hereof.

 

6.17         
Mutual Drafting. This Subscription Agreement is the joint product of the parties hereto and each provision hereof
has been subject to the mutual consultation, negotiation and agreement of the parties and shall not be construed for or against
any party hereto.

 

7.                  Disclosure.
Subscriber hereby consents to the publication and disclosure in (x) any Form 8-K filed by the Issuer with the Commission in
connection with the execution and delivery of the Study Merger Agreement, Joint Proxy Statement or Joint Proxy
Statement/Prospectus or any other filing with the Commission pursuant to applicable securities laws, in each case, as and to
the extent required by the federal securities laws or the Commission or any other securities authorities, and (y) any other
documents or communications provided by the Issuer or Study to any governmental authority or to securityholders of the
Issuer, in each case, as and to the extent required by applicable law or the Commission or any other governmental authority,
of Subscriber’s name and identity and the nature of Subscriber’s commitments, arrangements and understandings
under and relating to this Subscription Agreement and, if deemed required or appropriate by the Issuer or Study, a copy of
this Subscription Agreement. Subscriber will promptly provide any information reasonably requested by the Issuer, Study or
Magnet for any regulatory application or filing made or approval sought in connection with the Transactions (including
filings with the Commission).

 

    17

     

    

 

8.                 
Trust Account Waiver. Notwithstanding anything to the contrary set forth herein, Subscriber acknowledges that
the Issuer has established a trust account containing the proceeds of its initial public offering and from certain private placements
(collectively, with interest accrued from time to time thereon, the “Trust Account”). Subscriber agrees that
(i) it has no right, title, interest or claim of any kind in or to any monies held in the Trust Account, and (ii) it shall have
no right of set-off or any right, title, interest or claim of any kind (“Claim”) to, or to any monies in, the
Trust Account, in each case in connection with this Subscription Agreement, and hereby irrevocably waives any Claim to, or to any
monies in, the Trust Account that it may have in connection with this Subscription Agreement; provided, however, that nothing in
this Section 8 shall be deemed to limit Subscriber’s right, title, interest or claim to the Trust Account by virtue
of such Subscriber’s record or beneficial ownership of securities of the Issuer acquired by any means other than pursuant
to this Subscription Agreement, including, but not limited to, any redemption right with respect to any such securities of the
Issuer. In the event Subscriber has any Claim against the Issuer under this Subscription Agreement, Subscriber shall pursue such
Claim solely against the Issuer and its assets outside the Trust Account and not against the property or any monies in the Trust
Account. Subscriber agrees and acknowledges that such waiver is material to this Subscription Agreement and has been specifically
relied upon by the Issuer to induce the Issuer to enter into this Subscription Agreement and Subscriber further intends and understands
such waiver to be valid, binding and enforceable under applicable law. In the event the Subscriber, in connection with this Subscription
Agreement, commences any action or proceeding which seeks, in whole or in part, relief against the funds held in the Trust Account
or distributions therefrom or any of the Issuer’s stockholders, whether in the form of monetary damages or injunctive relief,
Subscriber shall be obligated to pay to the Issuer all of its legal fees and costs in connection with any such action in the event
that the Issuer prevails in such action or proceeding.

 

9.                 
Non-Reliance. Subscriber acknowledges that it is not relying upon, and has not relied upon, any statement,
representation or warranty made by any person, firm or corporation (including, without limitation, Study, any of its affiliates
or any of its control persons, officers, directors or employees), other than the representations and warranties of the Issuer expressly
set forth in this Subscription Agreement, in making its investment or decision to invest in the Issuer.

 

10.             
Rule 144. From and after such time as the benefits of Rule 144 promulgated under the Securities Act or any
other similar rule or regulation of the Commission that may allow Subscriber to sell securities of the Issuer to the public without
registration are available to holders of the Issuer’s common stock and until the third anniversary of the Closing Date, the
Issuer agrees to:

 

    18

     

    

 

10.1.1                  
 make and keep public information available, as those terms are understood and defined in Rule 144;

 

10.1.2                  
file with the Commission in a timely manner all reports and other documents required of the Issuer under the Securities
Act and the Exchange Act so long as the Issuer remains subject to such requirements and the filing of such reports and other documents
is required for the applicable provisions of Rule 144; and

 

10.1.3                  
furnish to Subscriber, promptly upon request, (x) a written statement by the Issuer, if true, that it has complied with
the reporting requirements of Rule 144, the Securities Act and the Exchange Act, (y) a copy of the most recent annual or quarterly
report of the Issuer and such other reports and documents so filed by the Issuer and (z) such other information as may be reasonably
requested to permit Subscriber to sell such securities pursuant to Rule 144 without registration.

 

If the Shares are eligible
to be sold without restriction under, and without the Issuer being in compliance with the current public information requirements
of, Rule 144 under the Securities Act, then at Subscriber’s request, the Issuer will cause its transfer agent to remove the
legend described in Section 2.1.6. In connection therewith, if required by the Issuer’s transfer agent, the Issuer
will promptly cause an opinion of counsel to be delivered to and maintained with its transfer agent, together with any other authorizations,
certificates and directions required by the transfer agent that authorize and direct the transfer agent to issue such Shares without
any such legend; provided, that, notwithstanding the foregoing, Issuer will not be required to deliver any such opinion, authorization,
certificate or direction if it reasonably believes that removal of the legend could result in or facilitate transfers of securities
in violation of applicable law.

 

[Signature Page Follows]

 

    19

     

    

 

IN WITNESS WHEREOF,
each of the Issuer and Subscriber has executed or caused this Subscription Agreement to be executed by its duly authorized representative
as of the date set forth below.

 

	 	Churchill Capital Corp II
	 	 
	 	By:	/s/
    Peter Seibold
	 	Name:	Peter Seibold
	 	Title:	Chief Financial Officer

 

     

     

    

 

 

	Accepted and agreed this 14th day of October, 2020.	 	 
	 	 	 
	SUBSCRIBER:	 	 
	 	 	 
	Signature of Subscriber:	 	Signature of Joint Subscriber, if applicable:
	 	 	 
	By:	/s/ Allison Green	 	By:	 
	Name: 	Allison Green	 	Name:	 
	Title: 	Chief Financial Officer	 	Title:	 
	 	 	 	 
	 	 	 
	Name of Subscriber:	 	Name of Joint Subscriber, if applicable:
	 	 	 
	(Please print.  Please indicate name and	 	(Please Print.  Please indicate name and
	capacity of person signing above)	 	capacity of person signing above)
	 	 	 
	 	 	 
	Name in which securities are to be registered (if different from the name of Subscriber listed directly above):	 	 
	 	 	 
	Email Address:	 	 
	 	 	 
	If there are joint investors, please check one:	 	 
	 	 	 
	 ̈ Joint Tenants with Rights of Survivorship	 	 
	 ̈ Tenants-in-Common	 	 
	 ̈ Community Property	 	 

 

	Subscriber’s EIN:	 	 	Joint Subscriber’s EIN:	 
	 	 	 
	Business Address-Street:	 	Mailing Address-Street (if different):
	 	 	 
	 	 	 
	City, State, Zip:	 	City, State, Zip:

 

	 	 	 
	Attn:	 	 	Attn:	 
	Telephone No.:	 	 	Telephone No.:	 
	Facsimile No.:	 	 	Facsimile No.:	 

 

     

     

    

 

SCHEDULE I

ELIGIBILITY REPRESENTATIONS OF SUBSCRIBER

 

		A.	QUALIFIED INSTITUTIONAL BUYER STATUS

(Please check the applicable subparagraphs):

 

		1.	 ̈ We are a “qualified institutional buyer” (as defined in Rule 144A under the Securities
Act of 1933, as amended (the “Securities Act”) (a “QIB”)).

 

		2.	 ̈ We are subscribing for the Shares as a fiduciary or agent for one or more investor accounts,
and each owner of such account is a QIB.

 

*** OR ***

 

		B.	INSTITUTIONAL ACCREDITED INVESTOR STATUS (Please check the applicable subparagraphs):

 

		1.	 ̈ We are an “accredited investor” (within the meaning of Rule 501(a) under the Securities
Act) or an entity in which all of the equity holders are accredited investors within the meaning of Rule 501(a) under the Securities
Act, and have marked and initialed the appropriate box on the following page indicating the provision under which we qualify as
an “accredited investor.”

 

		2.	 ̈ We are not a natural person.

 

*** AND ***

 

		C.	AFFILIATE STATUS

(Please check the applicable box) SUBSCRIBER:

 

		 ̈	is:

 

		 ̈	is not:

 

an “affiliate” (as
defined in Rule 144 under the Securities Act) of the Issuer or acting on behalf of an affiliate of the Issuer.

 

This page should be completed by Subscriber

and constitutes a part of the Subscription Agreement.

 

     

     

    

 

Rule 501(a) under the Securities Act, in
relevant part, states that an “accredited investor” shall mean any person who comes within any of the below listed
categories, or who the issuer reasonably believes comes within any of the below listed categories, at the time of the sale of the
securities to that person. Subscriber has indicated, by marking and initialing the appropriate box below, the provision(s) below
which apply to Subscriber and under which Subscriber accordingly qualifies as an “accredited investor.”

 

 ̈ Any bank as defined in section
3(a)(2) of the Securities Act, or any savings and loan association or other institution as defined in section 3(a)(5)(A) of the
Securities Act whether acting in its individual or fiduciary capacity;

 

 ̈ Any broker or dealer registered
pursuant to section 15 of the Securities Exchange Act of 1934, as amended;

 

 ̈ Any insurance company as
defined in section 2(a)(13) of the Securities Act;

 

 ̈ Any investment company registered
under the Investment Company Act of 1940, as amended (the “Investment Company Act”) or a business development
company as defined in section 2(a)(48) of the Investment Company Act;

 

 ̈ Any Small Business Investment
Company licensed by the U.S. Small Business Administration under section 301(c) or (d) of the Small Business Investment Act of
1958, as amended;

 

 ̈ Any plan established and
maintained by a state, its political subdivisions, or any agency or instrumentality of a state or its political subdivisions, for
the benefit of its employees, if such plan has total assets in excess of $5,000,000;

 

 ̈ Any employee benefit plan
within the meaning of the Employee Retirement Income Security Act of 1974, as amended (“ERISA”), if (i) the
investment decision is made by a plan fiduciary, as defined in section 3(21) of ERISA, which is either a bank, a savings and loan
association, an insurance company, or a registered investment adviser, (ii) the employee benefit plan has total assets in excess
of $5,000,000 or, (iii) such plan is a self-directed plan, with investment decisions made solely by persons that are “accredited
investors”;

 

 ̈ Any private business development
company as defined in section 202(a)(22) of the Investment Advisers Act of 1940, as amended;

 

 ̈ Any (i) corporation, limited
liability company or partnership, (ii) Massachusetts or similar business trust, or (iii) organization described in section 501(c)(3)
of the Internal Revenue Code of 1986, as amended, not formed for the specific purpose of acquiring the securities offered, and
with total assets in excess of $5,000,000;

 

 ̈ Any director, executive officer,
or general partner of the issuer of the securities being offered or sold, or any director, executive officer, or general partner
of a general partner of that issuer;

 

 ̈ Any natural person whose
individual net worth, or joint net worth with that person’s spouse, exceeds $1,000,000. For purposes of calculating a natural
person’s net worth: (a) the person’s primary residence shall not be included as an asset; (b) indebtedness that is
secured by the person’s primary residence, up to the estimated fair market value of the primary residence at the time of
the sale of securities, shall not be included as a liability (except that if the amount of such indebtedness outstanding at the
time of sale of securities exceeds the amount outstanding 60 days before such time, other than as a result of the acquisition of
the primary residence, the amount of such excess shall be included as a liability); and (c) indebtedness that is secured by the
person’s primary residence in excess of the estimated fair market value of the primary residence at the time of the sale
of securities shall be included as a liability;

 

 ̈ Any natural person who had
an individual income in excess of $200,000 in each of the two most recent years or joint income with that person’s spouse
in excess of $300,000 in each of those years and has a reasonable expectation of reaching the same income level in the current
year;

 

 ̈ Any trust, with total assets
in excess of $5,000,000, not formed for the specific purpose of acquiring the securities offered, whose purchase is directed by
a sophisticated person as described in Section 230.506(b)(2)(ii) of Regulation D; or

 

 ̈ Any entity in which all of
the equity owners are “accredited investors.”Exhibit 10.9

 

EXECUTION VERSION

 

EXECUTIVE EMPLOYMENT AGREEMENT

 

THIS EXECUTIVE EMPLOYMENT
AGREEMENT (this “Agreement”) is entered into as of October 13, 2020 (the “Signing Date”),
by and between JEFFREY R. TARR (the “Executive”) and Churchill Capital Corp II, a Delaware corporation (the
 “Company”).

 

W I T N E S S E T H:

 

WHEREAS, Software Luxembourg
Holding S.A. and the Company are parties to that certain merger agreement, dated as of October 12, 2020 (the “Merger
Agreement”);

 

WHEREAS, it is the
intent of the Executive and the Company that this Agreement will become effective upon the closing of the transactions contemplated
under the Merger Agreement (“Closing”);

 

WHEREAS, subject to
and conditioned upon the Closing, the Company wishes to employ the Executive in the capacity of its Chief Executive Officer, effective
as of the Closing (such date, the “Start Date”); and

 

WHEREAS, the Executive
is willing to accept such employment upon the terms and conditions set forth below and is committed to remaining in the Company’s
employ upon the terms and conditions set forth below.

 

NOW, THEREFORE, in
consideration of the mutual covenants herein contained, the parties agree as follows, effective upon the Closing; provided that,
in the event such Closing does not occur, the Company shall nevertheless honor and satisfy the provisions of Sections 5(b), 17(j) and
17(k)(ii) hereof regardless of the absence of an Employment Term, subject to Section 17(l) hereof:

 

1.            Term.
The Company agrees to employ the Executive, and the Executive agrees to remain in employment with the Company, from the Start Date
until the second anniversary of the Start Date (the “Initial Term”), unless terminated earlier in accordance
with Sections 6, 7, 8 or 9. Except with respect to Sections 13 through 17, which survive as set forth therein, this Agreement shall
expire at the end of the Term, or, in the case of the Executive’s earlier termination in accordance with Sections 6, 7, 8
or 9, when all obligations of the parties hereunder have been satisfied. The Initial Term shall be automatically extended for successive
one (1) year periods (each such extension term and the Initial Term, a “Term” and collectively, the “Employment
Term”) unless either party hereto gives notice of nonrenewal of the Term to the other party no later than six (6) months
prior to the expiration of the then-applicable Term. Notwithstanding the foregoing, if the Closing does not occur, the terms of
this Agreement will be null and void ab initio.

 

2.            Duties
and Scope of Employment.

 

(a)            Position.
The Company agrees to employ the Executive in the Denver, Colorado metropolitan area (the “Primary Work Location”)
as its Chief Executive Officer as of the Start Date. The Executive shall report to the Company’s Board of Directors (the
 “Board”) and shall have the authority and responsibilities customarily granted to the Chief Executive Officer.
In addition, during the Employment Term, the Executive shall serve as a member of the Board, and shall, in consultation with the
Board, reasonably lease and staff an office in his Primary Work Location.

 

     

     

    

 

(b)            Obligations.
During the Employment Term, the Executive shall devote his full business efforts and time to the Company and its affiliates and
shall not render services to any other person or entity without the consent of the Board. The foregoing, however, shall not preclude
the Executive from (i) serving on the boards of directors of not-for-profit entities, (ii) serving on the boards of directors
of up to two other corporations as the Board may approve from time to time (including the board of directors of EchoStar Corporation
for so long as such directorship does not interfere or conflict with the Executive’s responsibilities to the Company, provided,
that any determination regarding such interference or conflict shall be made in the Company’s reasonable discretion, and
upon a finding of any such interference or conflict, the Executive agrees and acknowledges that he shall immediately resign from
such directorship), (iii) engaging in other civic, charitable, non-profit, industry or trade associations, or religious activities
(including periodic speaking engagements which do not interfere or conflict with his responsibilities to the Company) or (iv) devoting
a reasonable amount of time to his personal and family investments which do not interfere or conflict with his responsibilities
to the Company.

 

(c)            Termination
and Offices Held. At the time that the Executive ceases to be an employee of the Company and its affiliates, the Executive
agrees that he shall resign from any offices he holds with the Company and any affiliates of the Company, including any boards
of directors or boards of managers positions held at the Company or any of its affiliates.

 

3.            Cash
Compensation.

 

(a)            Base
Salary. Effective as of the Start Date, the Company agrees to pay the Executive, as compensation for his services as Chief
Executive Officer, a base salary at an annual rate of $750,000 (the “Base Salary”). The Executive’s Base
Salary shall be subject to required withholding taxes, shall be subject to annual review by the Board, and shall not be decreased
during the Employment Term, provided that the foregoing prohibition shall not apply to decreases in base salary that do not exceed
10% (individually or in the aggregate) and that are applied uniformly to all senior managers of the Company.

 

(b)            Annual
Incentive Compensation. With respect to each fiscal year during the Employment Term beginning with the Company’s fiscal
year 2021, the Executive shall be eligible to receive an annual cash bonus (the “Annual Cash Incentive”) based
on performance objectives (for threshold, target and maximum) established for each such fiscal year by the Compensation Committee
of the Board (the “Committee”) in consultation with the Executive. The Executive’s target Annual Cash
Incentive amount for each such fiscal year will be 100% of Base Salary, and the maximum Annual Cash Incentive amount for each such
fiscal year will be 200% of Base Salary. Payment of any Annual Cash Incentive for any fiscal year shall be made at the same time
that bonuses are ordinarily paid to other senior executives of the Company, subject to the Executive’s continued employment
through the date of payment.

 

4.            Equity
Grant. Promptly but no more than thirty (30) days following the Start Date, the Executive shall receive an award of 1,000,000
options (the “Options”) in respect of Company common stock (a “Share”), with each such Option
to have an exercise price equal to the fair market value of a Share on the date of grant. The Options will vest ratably on a quarterly
basis over the four-year period following the Start Date, subject to the Executive’s continued employment through the applicable
vesting date. Notwithstanding the foregoing, the Options will vest in full upon a change in control (as such term is defined in
the definitive award document or applicable plan) or, if occurring earlier, upon the Executive’s termination due to death
or Disability (as defined below), which Options shall remain exercisable for the one-year period following any such termination;
provided that upon the Executive’s termination without Cause (as defined below) or for Good Reason (as defined below), vesting
shall continue in accordance with Section 9 below; and provided further that all Options (whether vested or unvested) shall
be immediately forfeited for no consideration upon a termination for Cause.

 

     

     

    

 

In addition, promptly but no more than
thirty (30) days following the Start Date, the Executive shall receive an award of 2,000,000 restricted stock units that will vest
ratably on a quarterly basis over the three-year period following the Start Date, subject to the Executive’s continued employment
through the applicable vesting date; provided, that, such restricted stock unit shall become fully vested upon a change in control
(as such term is defined in the definitive award document or applicable plan) or, if occurring earlier, upon the Executive’s
termination due to death or Disability; provided further that upon the Executive’s termination without Cause (as defined
below) or for Good Reason (as defined below), vesting shall continue in accordance with Section 9 below.

 

The definitive award agreements governing
the Options and restricted stock units granted pursuant to this Section 4 shall permit the Executive to satisfy payment of
any exercise price and/or withholding taxes, as applicable, through net exercise (for Options) and net Share withholding (for Options
and restricted stock units).

 

5.             Employee
Benefits and Expenses.

 

(a)            Benefits.
During the Employment Term, the Executive shall be entitled to participate in any health, welfare and other benefit plans, programs
or arrangements offered to other senior executives of the Company, subject in each case to the generally applicable terms and conditions
of the plan, program or arrangement in question as in effect from time to time. During the Employment Term, the Executive shall
also be entitled to paid time off per calendar year, subject to the Company’s vacation policy.

 

(b)            Business
Expenses. During the Employment Term, the Executive shall be authorized to incur necessary and reasonable travel, entertainment
and other business expenses in connection with his duties hereunder. The Company shall reimburse the Executive for such expenses
upon timely presentation of appropriate documentation, all in accordance with the Company’s generally applicable policies
as applicable to the Executive, as in effect from time to time.

 

6.             Involuntary
Termination. The Company may terminate the Executive’s employment for any reason, with or without Cause, including, but
not limited to, the reasons described below, by giving the Executive not less than thirty (30) days’ advance notice in writing
(in which event the Executive may become entitled to the payments and benefits described in Section 9 or 10, as applicable).
The date of the Executive’s termination of employment from the Company hereunder shall be referred to as the Executive’s
 “Termination Date.”

 

(a)            Termination
for Cause. The Company may terminate the Executive’s employment at any time for Cause. For all purposes under this Agreement,
 “Cause” shall mean (i) a willful failure by the Executive to substantially perform his duties hereunder,
other than a failure resulting from the Executive’s complete or partial incapacity due to physical or mental illness or impairment,
(ii) a willful act by the Executive which constitutes gross misconduct and which is materially injurious to the Company, (iii) the
Executive’s indictment of, conviction of, or no contest plea to, an act of theft, fraud or embezzlement, (iv) Executive’s
commission of a felony; (v) Executive’s breach, which is materially injurious to the Company, of any material Company
policy, including, without limitation, the Company’s sexual harassment policy or (vi) Executive’s breach of any
restrictive covenants which is materially injurious to the Company to which he is bound pursuant to any agreement with the Company
or its affiliates, including the restrictive covenants set forth in Section 13 of this Agreement (the “Restrictive
Covenants”). No act, or failure to act, by the Executive shall be considered “willful” unless committed (A) without
good faith and without a reasonable belief that the act or omission was in the Company’s best interest or (B) with gross
negligence. The Company’s notice of termination shall specify the nature of the Cause, and, unless the willful failure or
act giving rise to such notice is not by its nature curable by the Executive, the Executive shall have fifteen (15) days following
such notice to cure such failure or act, and, if so cured to the reasonable satisfaction of the Company, such failure or act shall
not constitute Cause hereunder.

 

     

     

    

 

(b)            Termination
for Disability. The Company may terminate the Executive’s employment for Disability. For all purposes under this Agreement,
 “Disability” shall mean that the Executive, at the time notice is given, has been unable to perform his duties
under this Agreement for a period of not less than six (6) consecutive months as a result of an illness or injury, as determined
for purposes of the Company’s long-term disability income insurance. The Company’s notice of termination shall specify
the nature of the Disability.

 

7.            Voluntary
Termination. The Executive may terminate his employment with the Company for any reason, including Good Reason, in which event
the Executive may become entitled to the payments and benefits described in Section 9 or 10, as applicable, subject in the
case of a Good Reason termination to Executive’s compliance with the notice provisions set forth in this Section 7.
In connection with a voluntary termination, other than a termination for Good Reason, the Executive shall give the Company not
less than six (6) months’ advance notice in writing. The Company may elect, in its sole discretion, to waive such six
(6) month advance written notice requirement. In connection with a termination that is a Good Reason termination, the Executive
shall give the Company not less than sixty (60) days’ advance notice in writing. The Company, in its sole discretion, may
elect to waive such sixty (60) day advance written notice requirement. Any waiver of notice by the Company shall not constitute
an involuntary termination under Section 6, and the termination shall continue to be considered a voluntary termination. For
all purposes under this Agreement, “Good Reason” shall mean (i) a demotion or reduction in the Executive’s
Base Salary, without his written consent, (ii) the Company’s failure to pay material compensation when due and payable,
(iii) a material reduction in the Executive’s responsibility or authority (such as due to the appointment of an executive
chairman or similarly functioning person) or a change in reporting such that the Executive is no longer reporting directly to the
Board, it being understood and agreed, however, that the appointment of an executive chairman as a result of an agreement with
MIH Ventures B.V. shall not under any circumstances constitute Good Reason so long as such person does not have responsibilities
or authority that diminish those of the Executive (or change his reporting relationship directly to the Board); (iv) removal
of the Executive from the Company’s Board or failure of the Executive to be re-elected to the Board, or (v) relocation
by more than fifty (50) miles of the Primary Work Location, provided, that any relocation to which the Executive has consented
shall not give rise to Executive’s ability to terminate his employment for Good Reason. The Executive must give the Board
advance notice in writing of the Executive’s decision to terminate his employment for Good Reason within ninety (90) days
of the initial occurrence of the condition that is the basis for such Good Reason resignation in order for the termination to be
treated as a Good Reason termination; provided, further, that Good Reason will only exist if, in the case
of a condition that may be cured, the Company fails to correct the deficiency within thirty (30) days of receipt of such notice.
The thirty (30) day cure period shall run contemporaneously with the sixty (60) day advance written notice period referenced above.

  

8.             Death.
The Executive’s employment under this Agreement automatically shall terminate on account of his death during the Employment
Term.

 

9.             Benefits
for Termination by the Company Without Cause or Resignation by the Executive for Good Reason. In the event that during the
Employment Term (i) the Company terminates the Executive’s employment for any reason other than Cause or Disability
or (ii) the Executive terminates his employment for Good Reason, the Executive shall be entitled to receive his Accrued Compensation
(defined in Section 10) and, subject to the Executive’s execution and delivery of a Waiver and Release Agreement pursuant
to Section 11 and the Executive’s continued compliance with the Restrictive Covenants, severance and benefits from the
Company (the “Severance”) consisting of (x) continued payment of two times the sum of (A) the Base
Salary and (B) target Annual Cash Incentive for the year in which termination occurs in accordance with the Company’s
normal payroll practices, as in effect on the Termination Date, for a period of twenty-four (24) months after the Termination Date
(the “Salary Continuation Payments”), (y) a bonus payment equal to the Annual Cash Incentive for the year
in which termination occurs based on actual performance and prorated to reflect the period of the fiscal year that has lapsed as
of the Termination Date, payable in accordance with Section 3(c) of this Agreement and (z) vesting of the Executive’s
equity awards due under Section 4 (or as granted thereafter) for the period of twelve (12) months following the date on which
termination occurs. Any payment under this Section 9 shall be subject to required withholding taxes. The Company’s election
not to extend the Employment Term in accordance with Section 1 shall be deemed a termination by the Company without Cause
and accordingly, Executive shall have the rights to severance and benefits as set forth in this Section 9.

 

10.           Benefits
for All Other Terminations. Subject to Section 4, in the event of (i) the Executive’s involuntary termination,
other than an involuntary termination by the Company without Cause for which Severance is owed in accordance with Section 9,
(ii) the Executive’s voluntary termination of employment from the Company other than for Good Reason, or (iii) the
Executive’s automatic termination of employment with the Company on account of his death, the Executive shall be entitled
to payment of compensation accrued through such date consisting of (i) any unpaid Base Salary owed to the Executive for services
rendered to the Termination Date, (ii) all vested benefits under applicable written plans and programs maintained by the Company
subject to the terms and conditions of such plans or programs, (iii) reasonable business expenses and disbursements incurred
by the Executive in accordance with the Company’s applicable written business expense reimbursement policy; and (iv) any
accrued but unpaid vacation payable in connection with a termination of employment of the Executive under the Company’s applicable
vacation policy (collectively, “Accrued Compensation”).

 

11.           Waiver
and Release of Claims. The Executive agrees that, as a condition to the receipt of the Severance pursuant to Section 9,
the Executive shall be required to (a) execute and deliver a waiver and release agreement, substantially in the form attached
hereto as Exhibit A, (the “Waiver and Release Agreement”) and (b) comply with the Restrictive
Covenants. The Executive shall execute and deliver the Waiver and Release Agreement within sixty (60) days of the Termination Date,
and the Company shall commence payment of the Salary Continuation Payments within sixty (60) days following the Termination Date
(with payment in arrears from the Termination Date ) provided, however, that if such sixty (60)-day period begins in one calendar
year and ends in a second calendar year, then the Salary Continuation Payments shall not commence until the second of such two
calendar years (regardless of whether Executive delivers the required Waiver and Release Agreement in the first calendar year or
in the second calendar year). If the Waiver and Release Agreement is not executed and delivered to the Company within such sixty
(60)-day period or is otherwise revoked, the Executive shall forfeit all rights to the Severance pursuant to Section 9.

 

     

     

    

 

12.           Nature
of Payments. For the avoidance of doubt, the Executive acknowledges and agrees that the payments set forth in Sections 9 constitute
liquidated damages for termination of the Executive’s employment during the Employment Term.

 

13.           Confidentiality;
Non-Solicitation; Non-Competition; and Nondisparagement.

 

(a)           Confidential
Information.

 

(i)            The
Executive acknowledges that, during the Employment Term the Executive shall be given access to and become acquainted with sensitive,
proprietary or confidential information relating to the Company and its affiliates, including without limitation, trade secrets,
processes, practices, pricing information, billing histories, customer requirements, customer lists, customer contacts, employee
lists, salary information, personnel matters, financial data, operating results, plans, contractual relationships, projections
for new business opportunities, new or developing business for the Company, technological innovations in any stage of development,
the Company’s financial data, long range or short range plans, any confidential or proprietary information of others licensed
to the Company, and all other data and information of a competition-sensitive nature (collectively, “Confidential Information”).
The Executive agrees that during the Employment Term or at any time thereafter, the Executive shall not, directly or indirectly,
communicate, disclose, or divulge to any Person, or use for the Executive’s benefit or the benefit of any Person, in any
manner, any Confidential Information or any other information concerning the conduct and details of the businesses of the Company
and its affiliates, except as required in the course of the Executive’s employment with the Company or as otherwise may be
required by applicable law.

 

(ii)            The
Executive acknowledges that the Confidential Information of the Company is a valuable, confidential, special, and unique asset
of the Company and its affiliates, expensive to produce and maintain, and essential for the profitable operation of their respective
businesses.

 

(iii)            All
documents relating to the businesses of the Company and its affiliates including, without limitation, documents, including electronic
records, whether prepared by the Executive or otherwise coming into the Executive’s possession, are the exclusive property
of the Company and its applicable affiliates and must not be removed from the premises of the Company, except as required in the
course of the Executive’s employment with the Company. The Executive shall return all such documents and electronic records
(including any copies thereof) to the Company upon the Termination Date or upon the earlier request of the Company or the Board.

 

This Agreement does
not limit the Executive’s ability to communicate with any governmental agency, file a charge or complaint with the Securities
and Exchange Commission or otherwise participate in any investigation or proceeding that may be conducted by any governmental agencies,
including by providing documents or other information, without notice to the Company. The Company acknowledges and agrees that
pursuant to 18 USC § 1833(b), the Executive may not be held liable under any criminal or civil federal or state trade secret
law for disclosure of a trade secret: (i) made in confidence to a government official, either directly or indirectly, or to
an attorney, solely for the purpose of reporting or investigating a suspected violation of law or (ii) in a complaint or other
document filed in a lawsuit or other proceeding, if such filing is made under seal.  The Company additionally acknowledges
and agrees that if Executive is suing an employer for retaliation based on the reporting of a suspected violation of law, then
he may disclose a trade secret to his attorney and use the trade secret information in the court proceeding, so long as any document
containing the trade secret is filed under seal and the individual does not disclose the trade secret except pursuant to court
order.

 

     

     

    

 

(b)           Non-Solicitation.
During the Employment Term and for a period of twelve (12) months following the Termination Date, the Executive shall not, except
with the Company’s express prior written consent, for the benefit of any entity or Person (including the Executive) (i) solicit,
induce, or encourage any employee of the Company, or any of its affiliates, to leave the employment of the Company or its affiliates,
(ii) solicit, induce, or encourage any customer, client, or independent contractor of the Company, or any of its affiliates,
to cease or reduce its business with or services rendered to the Company or its affiliates or (iii) hire (on behalf of the
Executive or any other person) any employee or independent contractor who has left the employment or other service of the Company
or its affiliates within one (1) year of the termination of such employee’s employment, or independent contractor’s
engagement, with the Company or its affiliates, provided, however, that nothing in this Section 13(b) shall
prohibit Executive from being involved with general solicitations for employment or in hiring anyone who responds to such solicitations.

 

(c)           Non-Competition.

 

(i)            During
the Employment Term, the Executive shall not, directly or indirectly be employed, engaged, concerned or interested in any other
business or undertaking (except a Permitted Investment (as defined below), or any activity disclosed to the Company so long as
such activities do not materially interfere with the Executive’s duties to the Company or any of its subsidiaries), other
than as authorized under Section 2(b) above or as approved by the Board prior to the date of this Agreement or from time
to time thereafter (such approval, in the case of charitable, pro bono or educational activities, not to be unreasonably withheld);
or

 

(ii)            During
the Employment Term and for a period of twelve (12) months following the Termination Date, the Executive shall not, directly or
indirectly engage in any activity (except as reasonably associated with a Permitted Investment) which the Board reasonably considers
may be, or become, materially harmful to and competitive with the business of the Company or any of its subsidiaries or which might
reasonably be considered to materially interfere with the performance of the Executive’s duties under this Agreement; provided
that, subject to Executive’s advance notification of such activity to the Board, it shall not constitute a competitive
activity for Executive, following the end of the Employment Term, to serve as a member of a board of directors or as an advisor
or employee for any company whose revenues from business that competes with that of the Company (as being conducted immediately
before the end of the Employment Term) do not exceed 10% of its revenues, or whose competitive business represents less than 10%
of the revenues of the Company.

 

“Permitted Investment”
means an investment: (a) comprising not more than 3% of the shares or other capital of a company (whether listed or not);
provided, that the relevant company in which the investment is made either (A) does not carry on a business which competes
with the Company or any of its subsidiaries or (B) does compete with the Company or any of its subsidiaries, but the investment
is a passive investment in shares or other securities of the relevant company which are listed on a securities exchange; or (b) which
is approved or consented to by the Board.

 

     

     

    

 

(d)            Non-Disparagement.
During the Employment Term and for a period of five (5) years following the Termination Date, the Executive shall not publicly
disparage the Company, its affiliates, or their respective officers or directors. Notwithstanding the foregoing, nothing in this
Agreement shall preclude the Executive or the Executive’s successor from making truthful statements that are required by
applicable law, regulation, or legal process. Likewise, during the Employment Term and for a period of five (5) years following
the Termination Date, members of the Board and members of the board of any subsidiary, and the respective officers of the Company
and any affiliate, shall not publicly disparage the Executive. Notwithstanding the foregoing, nothing in this Agreement shall preclude
members of the Board and members of the board of any subsidiaries, and the respective officers of the Company and any subsidiary,
from making truthful statements that are required by applicable law, regulation, or legal process.

 

14.           Cooperation
with Regard to Litigation. The Executive agrees to cooperate with the Company, during the Employment Term and after the Termination
Date, by making the Executive available to testify on behalf of the Company or any affiliate of the Company, in any action, suit,
or proceeding, whether civil, criminal, administrative, or investigative, and to assist the Company, or any affiliate of the Company,
in any such action, suit, or proceeding, by providing information and meeting and consulting with the Board or its representatives
or counsel, or representatives or counsel to the Company or any affiliate of the Company, as may be reasonably requested and after
taking into account the Executive’s post-termination responsibilities and obligations. The Company agrees to reimburse the
Executive, on an after-tax basis, for all reasonable expenses, including legal fees, actually incurred in connection with the Executive’s
provision of testimony or assistance; provided that, Executive shall be permitted to redact invoices for legal services
incurred to preserve attorney-client privilege.

 

15.           Section 280G
of the Code.

 

(a)            If
there is a change of ownership or effective control or change in the ownership of a substantial portion of the assets of the Company
(within the meaning of Section 280G of the Code) (a “Change in Control”) and any payment or benefit (including
payments and benefits pursuant to this Agreement) that the Executive would receive from the Company or otherwise (“Transaction
Payment”) would (i) constitute a “parachute payment” within the meaning of Section 280G of the
Code and (ii) but for this sentence, be subject to the excise tax imposed by Section 4999 of the Code (the “Excise
Tax”), then the Company shall cause to be determined, before any amounts of the Transaction Payment are paid to the Executive,
which of the following two alternative forms of payment would result in the Executive’s receipt, on an after-tax basis, of
the greater amount of the Transaction Payment notwithstanding that all or some portion of the Transaction Payment may be subject
to the Excise Tax: (A) payment in full of the entire amount of the Transaction Payment (a “Full Payment”), or
(B) payment of only a part of the Transaction Payment so that the Executive receives the largest payment possible without
the imposition of the Excise Tax (a “Reduced Payment”), and the Executive shall be entitled to payment of whichever
amount shall result in a greater after-tax amount for the Executive. For purposes of determining whether to make a Full Payment
or a Reduced Payment, the Company shall cause to be taken into account all applicable federal, state and local income and employment
taxes and the Excise Tax (all computed at the highest applicable marginal rate, net of the maximum reduction in federal income
taxes which could be obtained from a deduction of such state and local taxes). If a Reduced Payment is made, the reduction in payments
and/or benefits shall occur in the following order: (1) first, reduction of cash payments, in reverse order of scheduled payment
date (or if necessary, to zero), (2) then, reduction of non-cash and non-equity benefits provided to the Executive, on a pro
rata basis (or if necessary, to zero) and (3) then, cancellation of the acceleration of vesting of equity award compensation
in the reverse order of the date of grant of the Executive’s equity awards.

 

     

     

    

 

(b)            Unless
the Executive and the Company otherwise agree in writing, any determination required under this section shall be made in writing
by the Company’s independent public accountants (the “Accountants”), whose determination shall be conclusive
and binding upon the Executive and the Company for all purposes. For purposes of making the calculations required by this Section,
the Accountants may make reasonable assumptions and approximations concerning applicable taxes and may rely on reasonable, good
faith interpretations concerning the application of Sections 280G and 4999 of the Code. The Accountants shall provide detailed
supporting calculations to the Company and the Executive as requested by the Company or the Executive. The Executive and the Company
shall furnish to the Accountants such information and documents as the Accountants may reasonably request in order to make a determination
under this Section. The Company shall bear all costs the Accountants may reasonably incur in connection with any calculations contemplated
by this Section as well as any costs incurred by the Executive with the Accountants for tax planning under Sections 280G and
4999 of the Code.

 

(c)            Notwithstanding
the foregoing, in the event that no stock of the Company or its Affiliates is readily tradable on an established securities market
or otherwise (within the meaning of Section 280G of the Code) at the time of the Change in Control, the Company shall submit
to a vote of shareholders for approval the portion of the Transaction Payments that equals or exceeds three times Executive’s
 “base amount” (within the meaning of Section 280G of the Code) (the “Excess Parachute Payments”)
in accordance with Treas. Reg. §1.280G-1, and Executive shall cooperate with such vote of shareholders, provided that the
Executive may execute, but shall not be required to execute, any documentation subjecting Executive’s entitlement to all
Excess Parachute Payments to such shareholder vote.

 

16.           Section 409A
Savings Provisions.

 

(a)            Section 409A
Exemption. It is intended that the payments and benefits provided under this Agreement shall be exempt from the application
of the requirements of Section 409A of the Code and the regulations and other guidance issued thereunder (collectively, “Section 409A”).
Specifically, any taxable benefits or payments provided under this Agreement are intended to be separate payments that qualify
for the “short term deferral” exception to Section 409A to the maximum extent possible, and to the extent they
do not so qualify, are intended to qualify for the separation pay exceptions to Section 409A and to be paid in accordance
with Section 409A (if applicable), to the maximum extent possible.

 

(b)            Separation
from Service. The Executive shall be deemed to have a termination of employment for purposes of determining the timing of any
payments or benefits hereunder that are classified as deferred compensation only upon a “separation from service” within
the meaning of Section 409A.

 

     

     

    

 

(c)            Specified
Employee Provisions. Notwithstanding any other provision of this Agreement to the contrary, if at the time of the Executive’s
separation from service, (i) the Executive is a specified employee (within the meaning of Section 409A and using the
identification methodology selected by the Company from time to time), and (ii) the Company makes a good faith determination
that an amount payable on account of such separation from service to the Executive constitutes deferred compensation (within the
meaning of Section 409A), the payment of which is required to be delayed pursuant to the six (6)-month delay rule set
forth in Section 409A in order to avoid taxes or penalties under Section 409A (the “Delay Period”),
then the Company shall not pay such amount on the otherwise scheduled payment date but shall instead pay it in a lump sum on the
first business day after such Delay Period (or upon the Executive’s death, if earlier), together with interest for the Delay
Period, compounded annually, equal to the prime rate (as published in the Wall Street Journal) in effect as of the dates the payments
should otherwise have been provided. To the extent that any benefits to be provided during the Delay Period are considered deferred
compensation under Section 409A provided on account of a separation from service, and such benefits are not otherwise exempt
from Section 409A, the Executive shall pay the cost of such benefit during the Delay Period, and the Company shall reimburse
the Executive, to the extent that such costs would otherwise have been paid by the Company or to the extent that such benefits
would otherwise have been provided by the Company at no cost to the Executive, the Company’s share of the cost of such benefits
upon expiration of the Delay Period, and any remaining benefits shall be reimbursed or provided by the Company in accordance with
the procedures specified herein.

 

(d)            Expense
Reimbursements. (i) Any amount that the Executive is entitled to be reimbursed under this Agreement shall be reimbursed
to the Executive as promptly as practical and in any event not later than the last day of the calendar year after the calendar
year in which the expenses are incurred; (ii) any right to reimbursement or in kind benefits shall not be subject to liquidation
or exchange for another benefit; and (iii) the amount of the expenses eligible for reimbursement during any taxable year shall
not affect the amount of expenses eligible for reimbursement in any other taxable year.

 

17.           Miscellaneous
Provisions.

 

(a)            Delivery
of Notice. Notices and all other communications contemplated by this Agreement shall be in writing and shall be deemed to have
been duly given when personally delivered or when mailed by certified mail, return receipt requested and postage prepaid. In the
case of the Executive, mailed notices shall be addressed to him at the home address which he most recently communicated to the
Company in writing. In the case of the Company, mailed notices shall be addressed to its corporate headquarters, and all notices
shall be directed to the attention of its Secretary. For all purposes under this Agreement, the employment relationship shall terminate
on the date properly specified in the notice of termination, and any waiver of such notice shall be valid only if it is made in
writing and expressly refers to the applicable notice requirement described in Section 6 or 7, as applicable.

 

(b)            Waiver.
No provision of this Agreement shall be modified, waived or discharged unless the modification, waiver or discharge is agreed to
in writing and signed by the Executive and by the Company with the approval of the Board. No waiver by either party of any breach
of, or of compliance with, any condition or provision of this Agreement by the other party shall be considered a waiver of any
other condition or provision or of the same condition or provision at another time.

 

(c)            Assignment
and Successors. The Executive shall not assign any right or delegate any obligation hereunder without the Company’s written
consent, and any purported assignment or delegation by the Executive without the Company’s written consent shall be void.
This Agreement may be assigned by the Company to a solvent Person which is an affiliate having (or a successor in interest to)
substantially all of the business operations and assets of the Company. Upon such assignment, the rights and obligations of the
Company hereunder shall become the rights and obligations of such affiliate or successor Person. “Person” means
any individual, corporation, partnership, limited liability company, association, trust or other entity or organization, including
a government or political subdivision or an agency or instrumentality thereof. This Agreement shall be binding upon and inure to
the benefit of the parties hereto and their respective heirs, legal representatives, successors and permitted assigns.

 

     

     

    

 

(d)            Whole
Agreement. Effective as of the Signing Date, this Agreement supersedes any prior agreement between the Executive and the Company
(including any verbal agreements and the previously negotiated term sheet relating to the terms of this Agreement).

 

(e)            Choice
of Law. The validity, interpretation, construction and performance of this Agreement shall be governed by the laws of the State
of Delaware, other than any conflicts or choice of law rules or principles thereof.

 

(f)            Severability.
The invalidity or unenforceability of any provision or provisions of this Agreement shall not affect the validity or enforceability
of any other provision hereof, which shall remain in full force and effect.

 

(g)            Arbitration.
Any dispute or controversy arising under or in connection with this Agreement shall be settled exclusively by arbitration conducted
in the city in which the Primary Work Location is located, by three (3) arbitrators. The Executive and the Company shall each
select one (1) arbitrator and those two (2) designated arbitrators shall select a third (3rd) arbitrator.
The arbitration shall not be administered by the American Arbitration Association; however, the arbitration shall be conducted
by the three (3) selected arbitrators using the procedural rules of the Employment Arbitration Rules and Mediation
Procedures of the American Arbitration Association in effect at the time of submission to arbitration. Judgment may be entered
on the arbitrators’ award in any court having jurisdiction. For purposes of entering any judgment upon an award rendered
by the arbitrators, the Company and the Executive hereby consent to the jurisdiction of any or all of the following courts: (i) the
United States District Court in or nearest to the city in which either the Primary Work Location is situated or the Company’s
headquarters are located, or (ii) any other court having jurisdiction. The Company and the Executive further agree that any
service of process or notice requirements in any such proceeding shall be satisfied if the rules of such court relating thereto
have been substantially satisfied. The Company and the Executive hereby waive, to the fullest extent permitted by applicable law,
any objection which it may now or hereafter have to such jurisdiction and any defense of inconvenient forum. The Company and the
Executive hereby agree that a judgment upon an award rendered by the arbitrators may be enforced in other jurisdictions by suit
on the judgment or in any other manner provided by law. Each party shall bear its or the Executive’s costs and expenses arising
in connection with any arbitration proceeding pursuant to this Section 17(g). Notwithstanding any provision in this Section 17(g),
the Executive shall be paid compensation due and owing under this Agreement during the pendency of any dispute or controversy arising
under or in connection with this Agreement. Any dispute or claim in law or equity, whether based on contract or tort or otherwise,
relating to or arising out of the employment of the Executive by the Company, other than a claim based on a statute providing an
exclusive means of enforcement, shall be settled exclusively by final arbitration in accordance with the labor arbitration rules of
the American Arbitration Association in effect at the time the arbitration is initiated. Any claim or dispute subject to arbitration
shall be deemed waived, and forever barred, if not presented for arbitration within six (6) months of the date when the claim
or dispute arose.

 

     

     

    

 

(h)            WAIVER
OF JURY TRIAL. TO THE EXTENT APPLICABLE, EACH OF THE PARTIES TO THIS AGREEMENT HEREBY AGREES TO WAIVE ITS RESPECTIVE RIGHTS
TO A JURY TRIAL FOR ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING OUT OF THIS AGREEMENT OR ANY DEALINGS BETWEEN THEM RELATING
TO THE SUBJECT MATTER OF THIS AGREEMENT.

 

(i)            No
Conflicts. The Executive represents, warrants and covenants that (a) the Executive has read and understands this Agreement,
is fully aware of its legal effect, has not acted in reliance upon any representations or promises made by the Company other than
those contained in writing herein, and has entered into this Agreement freely based on his own judgment, (b) the Executive
has the full right, authority and capacity to enter into this Agreement and to perform the Executive’s obligations hereunder,
(c) the Executive is not bound by any agreement that conflicts with or prevents or restricts the full performance of the Executive’s
duties and obligations to the Company hereunder during or after the Employment Term and (d) the execution and delivery of
this Agreement shall not result in any breach or violation of, or a default under, any existing obligation, commitment or agreement
to which the Executive is subject.

 

(j)            Attorney’s
and Advisory Fees. The Company shall reimburse Executive (or pay directly) for attorney’s fees and advisory fees incurred
by the Executive in connection with the negotiation and execution of this Agreement and related term sheet that was negotiated
prior to entry into this Agreement; provided that, the aggregate reimbursement in respect of the foregoing shall not exceed $25,000.
The same reimbursement terms shall apply to any future renewals, extensions, or modifications to this Agreement that are initiated
by the Company.

 

(k)            Indemnification. 
The Company hereby agrees to indemnify the Executive and hold the Executive harmless to the maximum extent provided or allowable
under the Company’s organizational documents against and in respect of any and all actions, suits, proceedings, claims, demands,
judgments, costs, expenses (including reasonable attorney’s fees), losses, and damages resulting from the Executive’s
good faith performance (i) of the Executive’s duties and obligations with the Company during the Employment Term, and
(ii) of the Executive’s services before the Employment Term relating to the Merger Agreement or the Closing.

 

(l)            Trust
Account Waiver. Notwithstanding anything to the contrary set forth herein, Executive acknowledges that the Company has established
a trust account containing the proceeds from certain private placements (collectively, with interest accrued from time to time
thereon, the “Trust Account”). Executive agrees that (i) he has no right, title, interest or claim of any kind
in or to any monies held in the Trust Account, and (ii) he shall have no right of set-off or any right, title, interest or
claim of any kind (“Claim”) to, or to any monies in, the Trust Account, in each case in connection with this Agreement,
and hereby irrevocably waives any Claim to, or to any monies in, the Trust Account that he may have in connection with this Agreement;
provided, however, that nothing in this Section 17(l) shall be deemed to limit Executive’s right, title, interest
or claim to the Trust Account by virtue of Executive’s record or beneficial ownership of securities of the Company acquired
by any means other than pursuant to this Agreement, including, but not limited to, any redemption right with respect to any such
securities of the Company. In the event Executive has any Claim against the Company under this Agreement, Executive shall pursue
such Claim solely against the Company and its assets outside the Trust Account and not against the property or any monies in the
Trust Account. Executive agrees and acknowledges that such waiver is material to this Agreement and has been specifically relied
upon by the Company to induce the Company to enter into this Agreement and Executive further intends and understands such waiver
to be valid, binding and enforceable under applicable law. In the event Executive, in connection with this Agreement, commences
any action or proceeding which seeks, in whole or in part, relief against the funds held in the Trust Account or distributions
therefrom or any of the Company’s stockholders, whether in the form of monetary damages or injunctive relief, Executive shall
be obligated to pay to the Company all of its legal fees and costs in connection with any such action in the event that the Executive
prevails in such action or proceeding.

 

     

     

    

 

IN WITNESS WHEREOF, each of the parties
has executed this Agreement, in the case of the Company by its duly authorized officer, as of the day and year first above written.

 

	 	EXECUTIVE: 
	 	 
	 	 
	 	/s/ Jeffrey R. Tarr
	 	Jeffrey R. Tarr    
	 	 
	 	 
	 	Churchill Capital Corp II     
	 	 
	 	 
	 	By:	/s/ Michael Klein
	 	Name: Michael Klein 
	 	Title: Authorized Signatory
	 	 

 

     

     

    

 

EXHIBIT A 

WAIVER AND RELEASE AGREEMENT

 

This Waiver and General
Release Agreement (the “Agreement”) is being entered into between Jeffrey R. Tarr (“Executive”)
and Churchill Capital Corp II, a Delaware corporation (the “Company”), in connection with the termination of
Executive’s employment with the Company as of [Month, Day], [Year] (the “Termination Date”), in consideration
of the severance (the “Severance”) provided to Executive pursuant to and in accordance with the Executive Employment
Agreement, dated October 13, 2020, by and between Executive and the Company (the “Employment Agreement”).
Executive and the Company are referred to collectively as the “Parties.”

 

1.            General
Release. Except for any rights granted under this Agreement, Executive, for himself, and for his heirs, assigns, executors
and administrators, hereby releases, remises and forever discharges the Company, its parents, subsidiaries, joint ventures, affiliates,
divisions, predecessors, successors, assigns, and each of their respective directors, officers, partners, attorneys, shareholders,
administrators, employees, agents, representatives, employment benefit plans, plan administrators, fiduciaries, trustees, insurers
and re-insurers, and all of their predecessors, successors and assigns (collectively, the “Releasees”) of and
from all claims, causes of action, covenants, contracts, agreements, promises, damages, disputes, demands, and all other manner
of actions whatsoever, in law or in equity, that Executive ever had, may have had, now has, or that Executive’s heirs, assigns,
executors or administrators hereinafter can, shall or may have, whether known or unknown, asserted or unasserted, suspected or
unsuspected, as a result of or related to Executive’s employment with the Company, the termination of that employment, or
any act or omission which has occurred at any time up to and including the date of the execution of this Release (the “Released
Claims”).

 

(a)            Released
Claims. The Released Claims released include, but are not limited to, any claims for monetary damages; any claims related to
Executive’s employment with the Company or the termination thereof; any claims to severance or similar benefits (except as
provided below in Section 1.c.); any claims to expenses, attorneys’ fees or other indemnities; any claims
to options or other interests in or securities of the Company; any claims based on any actions or failures to act that occurred
on or before the date of this Agreement; and any claims for other personal remedies or damages sought in any legal proceeding or
charge filed with any court or federal, state or local agency either by Executive or by any person claiming to act on Executive’s
behalf or in Executive’s interest. Executive understands that the Released Claims may have arisen under different local,
state and federal statutes, regulations, or common law doctrines. Executive hereby specifically, but without limitation, agrees
to release all Releasees from any and all claims under each of the following laws:

 

(i)            Antidiscrimination
laws, such as Title VII of the Civil Rights Act of 1964, as amended, and Executive Order 11246 (which prohibit discrimination
based on race, color, national origin, religion, or sex); Section 1981 of the Civil Rights Act of 1866 (which prohibits discrimination
based on race or color); the Americans with Disabilities Act and Sections 503 and 504 of the Rehabilitation Act of 1973 (which
prohibit discrimination based upon disability); the Age Discrimination in Employment Act, as amended, 29 U.S.C. Section 621 et
seq. (which prohibits discrimination on the basis of age); the Equal Pay Act (which prohibits paying men and women unequal
pay for equal work); or any other local, state or federal statute, regulation, common law or decision concerning discrimination,
harassment, or retaliation on these or any other grounds or otherwise governing the employment relationship.

 

     

     

    

 

(ii)            Other
employment laws, such as the federal Worker Adjustment and Retraining Notification Act of 1988 (known as WARN, which requires
advance notice of certain workforce reductions); the Employee Retirement Income Security Act of 1974 (which, among other things,
protects employee benefits); the Fair Labor Standards Act of 1938 (which regulates wage and hour matters); the Family and Medical
Leave Act of 1993 (which requires employers to provide leaves of absence under certain circumstances); and any other federal, state,
or local statute, regulation, common law or decision relating to employment, reemployment rights, leaves of absence or any other
aspect of employment.

 

(iii)            Other
laws of general application, such as federal, state, or local laws enforcing express or implied employment agreements or other
contracts or covenants, or addressing breaches of such agreements, contracts or covenants; federal, state or local laws providing
relief for alleged wrongful discharge or termination, physical or personal injury, emotional distress, fraud, intentional or negligent
misrepresentation, defamation, invasion of privacy, violation of public policy or similar claims; common law claims under any tort,
contract or other theory now or hereafter recognized, and any other federal, state, or local statute, regulation, common law doctrine,
or decision regulating or regarding employment.

 

(b)           Participation
in Agency Proceedings. Nothing in this Agreement shall prevent Executive from filing a charge (including a challenge to the
validity of this Agreement) with the Equal Employment Opportunity Commission (the “EEOC”), the National Labor
Relations Board (the “NLRB”), or other similar federal, state or local agency, or from participating in any
investigation or proceeding conducted by the EEOC, the NLRB or similar federal, state or local agencies. However, by entering into
this Agreement, Executive understands and agrees that Executive is waiving any and all rights to recover any monetary relief or
other personal relief as a result of any such EEOC, NLRB or similar federal, state or local agency proceeding, including any subsequent
legal action. Notwithstanding the foregoing, nothing in this Agreement prohibits or restricts Executive (or Executive’s attorney)
from filing a charge or complaint with the Securities and Exchange Commission (the “SEC”), the Financial Industry
Regulatory Authority (“FINRA”), or any other securities regulatory agency or authority. Executive further understands
that this Agreement does not limit Executive’s ability to communicate with any securities regulatory agency or authority
or otherwise participate in any investigation or proceeding that may be conducted by any securities regulatory agency or authority
without notice to the Company. This Agreement does not limit Executive’s right to receive an award for information provided
to the SEC staff or any other securities regulatory agency or authority.

 

(c)           Claims
Not Released. The Released Claims do not include claims by Executive for: (1) payment of the Severance
or reimbursements due under the Employment Agreement; (2) previously vested benefits under any the Company-sponsored benefits
plan, including without limitation the equity awards granted pursuant to Section 4 of the Employment Agreement; (3) indemnification
and advancement of expenses under the Company’s certificate of incorporation or bylaws, and (4) any rights that cannot
by law be released by private agreement.

 

(d)           No
Existing Claims or Assignment of Claims. Executive represents and warrants that he has not previously filed or joined in any
claims that are released in this Agreement and that he has not given or sold any portion of any claims released herein to anyone
else, and that he will indemnify and hold harmless the Company and the Releasees from all liabilities, claims, demands, costs,
expenses and/or attorneys’ fees incurred as a result of any such prior assignment or transfer.

 

     

     

    

 

(e)           Defend
Trade Secrets Act. The Company acknowledges and agrees that pursuant to 18 USC § 1833(b), the Executive may not be held
liable under any criminal or civil federal or state trade secret law for disclosure of a trade secret: (i) made in confidence
to a government official, either directly or indirectly, or to an attorney, solely for the purpose of reporting or investigating
a suspected violation of law or (ii) in a complaint or other document filed in a lawsuit or other proceeding, if such filing
is made under seal.  The Company additionally acknowledges and agrees that if Executive is suing an employer for retaliation
based on the reporting of a suspected violation of law, then he may disclose a trade secret to his attorney and use the trade secret
information in the court proceeding, so long as any document containing the trade secret is filed under seal and the individual
does not disclose the trade secret except pursuant to court order.

 

(f)           Acknowledgement
of Legal Effect of Release. BY SIGNING THIS AGREEMENT, EXECUTIVE UNDERSTANDS THAT HE IS WAIVING ALL RIGHTS HE MAY HAVE
HAD TO PURSUE OR BRING A LAWSUIT OR MAKE ANY LEGAL CLAIM AGAINST THE COMPANY OR THE RELEASEES, INCLUDING, BUT NOT LIMITED
TO, CLAIMS THAT IN ANY WAY ARISE FROM OR RELATE TO EXECUTIVE’S EMPLOYMENT OR THE TERMINATION OF THAT EMPLOYMENT, FOR ALL
OF TIME UP TO AND INCLUDING THE DATE OF THE EXECUTION OF THIS AGREEMENT. EXECUTIVE FURTHER UNDERSTANDS THAT BY SIGNING THIS AGREEMENT,
EXECUTIVE IS PROMISING NOT TO PURSUE OR BRING ANY SUCH LAWSUIT OR LEGAL CLAIM SEEKING MONETARY OR OTHER RELIEF.

 

2.            General
Provisions. This Agreement contains the entire understanding and agreement between the Parties relating to the subject matter
of this Agreement, and supersedes any and all prior agreements or understandings between the Parties pertaining to the subject
matter hereof. This Agreement may not be altered or amended except by an instrument in writing signed by both Parties. Executive
has not relied upon any representation or statement outside this Agreement with regard to the subject matter, basis or effect of
this Agreement. This Agreement will be governed by, and construed in accordance with, the laws of the State of Delaware, excluding
the choice of law rules thereof, and shall be subject to the arbitration provisions under the Employment Agreement. This Agreement
will be binding upon and inure to the benefit of the Parties and their respective representatives, successors and permitted assigns.
If any one or more of the provisions of this Agreement, or any part thereof, will be held to be invalid, illegal or unenforceable,
the validity, legality and enforceability of the remainder of this Agreement will not in any way be affected or impaired thereby.

 

3.            No
Admission; Attorneys Fees. Executive agrees that nothing contained in this Agreement will constitute or be treated as an admission
of liability or wrongdoing by either Executive or the Company. In any action to enforce the terms of this Agreement, the prevailing
Party will be entitled to recover its costs and expenses, including reasonable attorneys’ fees.

 

4.            ADEA
Acknowledgement/Time Periods. With respect to the General Release in Section 1 of this Agreement, Executive
agrees and understands that by signing this Agreement, Executive is specifically releasing all claims under the Age Discrimination
in Employment Act, as amended, 29 U.S.C. Section 621 et seq.  Executive acknowledges that he has carefully
read and understands this Agreement in its entirety and executes it voluntarily and without coercion.

 

     

     

    

 

(a)            Consideration
Period. Executive is hereby advised to consult with a competent, independent attorney of Executive’s choice, at Executive’s
expense, regarding the legal effect of this Agreement before signing it. Executive shall have [twenty-one (21)] / [forty-five (45)]
days from receipt of this Agreement to consider whether to execute it, but Executive may voluntarily choose to execute this Agreement
before the end of the [twenty-one (21)] / [forty-five (45)] day period.

 

(b)            Revocation
Period. Executive understands that Executive has seven (7) days following his execution of this Agreement to revoke it
in writing, and that this Agreement is not effective or enforceable until after this seven (7) day period has expired without
revocation. If Executive wishes to revoke this Agreement after signing it, Executive must provide written notice of Executive’s
decision to revoke the Agreement to the Company, Attention: _______, _______ by no later than 12:01 a.m. on the eighth (8th)
calendar day after the date by which Executive has signed this Agreement (the “Revocation Deadline”).

 

5.            Execution.
Executive understands and agrees that this Agreement shall be null and void and have no legal or binding effect whatsoever if:
(1) Executive signs but then timely revokes the Agreement before the Revocation Deadline or (2) the Agreement is not
signed by Executive on or before the [twenty-first (21st)] / [forty-fifth (45th)] day after Executive receives
it.

 

[SIGNATURE PAGE FOLLOW]

 

     

     

    

 

BY
SIGNING BELOW, EXECUTIVE REPRESENTS AND WARRANTS THAT EXECUTIVE HAS FULL LEGAL CAPACITY TO ENTER INTO THIS AGREEMENT, EXECUTIVE
HAS CAREFULLY READ AND UNDERSTANDS THIS AGREEMENT IN ITS ENTIRETY, HAS HAD A FULL OPPORTUNITY TO REVIEW THIS AGREEMENT WITH AN
ATTORNEY OF EXECUTIVE’S CHOOSING, AND HAS EXECUTED THIS AGREEMENT VOLUNTARILY, WITHOUT DURESS, COERCION OR UNDUE INFLUENCE.

 

IN WITNESS WHEREOF,
the undersigned, intending to be bound hereby, has agreed to the terms and conditions of this Agreement as of the date set forth
below.

 

	 	EXECUTIVE:
	 	 
	 	 
	 	 
	 	Jeffrey R. Tarr
	 	 
	 	Date: _________________, 2020___

 

ELECTION TO EXECUTE PRIOR TO EXPIRATION

OF THE [TWENTY-ONE (21)] / [FORTY-FIVE (45)]-DAY CONSIDERATION PERIOD

 

I, Jeffrey R. Tarr,
understand that I have [twenty-one (21)] / [forty-five (45)] days within which to consider and execute the attached Waiver and
General Release Agreement. However, after having an opportunity to consult counsel, I have freely and voluntarily elected
to execute the Waiver and General Release Agreement before such [twenty-one (21)] / [forty-five (45)]-day period has expired.

 

	 	 	 
	Date	 	Signature

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00315-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00315-of-00352.parquet"}]]